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Abstract We develop a physiological model of granulopoiesis which includes
explicit modelling of the kinetics of the cytokine granulocyte colony-stimulating
factor (G-CSF) incorporating both the freely circulating concentration and the
concentration of the cytokine bound to mature neutrophils. G-CSF concentra-
tions are used to directly regulate neutrophil production, with the rate of
differentiation of stem cells to neutrophil precursors, the effective proliferation
rate in mitosis, the maturation time, and the release rate from the mature
marrow reservoir into circulation all dependent on the level of G-CSF in the
system. The dependence of the maturation time on the cytokine concentra-
tion introduces a state-dependent delay into our differential equation model,
and we show how this is derived from an age-structured partial differential
equation model of the mitosis and maturation, and also detail the derivation
of the rest of our model. The model and its estimated parameters are shown
to successfully predict the neutrophil and G-CSF responses to a variety of
treatment scenarios, including the combined administration of chemotherapy
and exogenous G-CSF. This concomitant treatment was reproduced without
any additional fitting to characterise drug-drug interactions.
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1 Introduction
We present a new model of granulopoiesis, in which the production of neu-
trophils is governed by a negative feedback loop between the neutrophils and
granulocyte colony stimulating factor (G-CSF). G-CSF is the principal cy-
tokine known to regulate neutrophil production and in our model it is used
to moderate differentiation of stem cells, apoptosis of proliferating neutrophil
precursors, the speed at which neutrophils mature and the rate that mature
neutrophils are released from the marrow reservoir. To facilitate this, we derive
not only new functions for the pharmacodynamic effects of G-CSF, but also
a new model of the G-CSF kinetics which incorporates cytokine binding and
internalisation by the neutrophils. We dispense with the mass action law as-
sumption made in some previous models and directly model the concentration
of both circulating G-CSF and G-CSF bound to neutrophils. This improved
kinetic model furnishes us with G-CSF concentrations which are considerably
more accurate than our previous models so we are able to use them to directly
drive the pharmacodynamic effects and finally form a fully closed cytokine-
neutrophil feedback loop.
At homeostasis the dominant removal mechanism for G-CSF is internali-
sation by neutrophils after it binds to receptors on these cells [32]. This gives
rise to a negative feedback mechanism on the G-CSF pharmacokinetics (PKs)
whereby large concentrations of neutrophils result in G-CSF being removed
from circulation, in turn leading to low concentrations of circulating G-CSF.
On the other hand if neutrophil concentrations are reduced then G-CSF is not
cleared from circulation as quickly and circulating concentrations increase as a
result. The feedback loop is completed by the pharmacodynamic (PD) effects
of the G-CSF: elevated (depressed) G-CSF levels lead to increased (decreased)
neutrophil production. Due to this feedback, using the simple paradigm that
neutrophil concentration is a cipher for the cytokine concentration (with one
low when the other is high), it is possible to derive granulopoiesis models with-
out explicitly modelling the cytokines. This is particularly useful because it is
not universally agreed where or how the multitude of identified cytokines all
act.
The mathematical modelling of granulopoiesis has a long and rich history
[4,5,9,11,18,20,25,27,28,53,54,56,57,61,72,65,66,68] but one of the earliest
and most complete treatments is that of Rubinow [49] which incorporates a
number of features that we retain in our model, including active proliferation,
maturation, a marrow reservoir and free exchange between the circulating and
marginal blood neutrophil pools. Rubinow’s model, however, predates the dis-
covery and characterisation of G-CSF and so it uses neutrophil concentrations
as a cipher for the cytokine and its effects. Subsequent physiological models
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have also all incorporated at least some elements of this cytokine paradigm in
their modelling. Some authors have been principally interested in neutrophil
pathologies, including cyclical neutropenia, chronic myeloid leukemia, and
myelosuppression during chemotherapy, while others have primarily studied
the effects of G-CSF mimetics. Many models of cyclic neutropenia, including
[9,18,25,33] and [55] acknowledge the role of G-CSF in neutrophil production
and pathologies but rely on the cytokine paradigm to drive the pharmaco-
dynamic responses. A number of modelling approaches have been proposed,
including compartmental ODE models [53,21,46,22,30,69], delay differential
equations (DDEs) incorporating statistical distributions to model delays [66,
65], and DDEs derived from age-structured partial differential equation (PDE)
models, like the one developed in this work [5,11,20].
In recent years, synthetic forms of G-CSF have been developed and are
administered to patients for a variety of reasons, including to treat cyclical
neutropenia or as an adjuvant during chemotherapy [12,13,40]. However, the
administration of exogenous G-CSF breaks the cytokine paradigm and it is
possible for neutrophil and G-CSF concentrations to both be elevated at the
same time. This breakdown of the natural feedback relationship can cause
physiological models that use the paradigm to mischaracterise the elimination
dynamics of G-CSF. For example, both [30] and [11] overestimate the renal
clearance of G-CSF so much as to essentially eliminate the contribution of
neutrophil-mediated internalisation, even though they each include this non-
linear clearance in their models. If elevated neutrophil concentrations are used
to drive the system dynamics on the assumption that corresponding G-CSF
concentrations are reduced when they are in fact elevated, the modelled effects
will act in the opposite sense to the physiology. As a consequence, the model
will either develop instabilities and/or give a poor fit to observed dynamics.
The mischaracterisation of G-CSF elimination dynamics was the impetus
for the current work. Consequently, we will not use the neutrophil concentra-
tion as a cipher for the G-CSF concentration, but will model both the G-CSF
pharmacokinetics and pharmacodynamics (PK/PD) in detail. For this, we
develop a novel pharmacokinetic model of G-CSF which includes both un-
bound and bound blood concentrations. The G-CSF concentrations given by
this kinetic model are then used to drive the pharmacodynamic effects of the
cytokine, in a fully formed negative feedback loop.
We begin by summarising the granulopoiesis model in Section 2. Its devel-
opment is then extensively detailed in Section 3, beginning from the stem cells
in Section 3.1. The novel pharmacokinetic G-CSF model incorporating bound
and unbound blood concentrations is motivated and developed in Section 3.2.
There we show how the hypothesis of an equilibrium between bound and un-
bound concentrations is not satisfied for G-CSF, necessitating the inclusion of
more complex kinetics in its pharmacokinetic model. Next, the derivation of
the DDE granulopoiesis model is given in Section 3.3 and the pharmacody-
namic model of G-CSF is developed in Section 3.4. Models of the exogenous
drugs considered in our study are detailed in Section 3.5. Having laid the
foundations of our model, the various methods of parameter estimation and
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fitting used for our analyses are subsequently explained in Section 4. These
approaches include model-specific constraints, as seen in Sections 4.1 and 4.3,
while fitting procedures from published data are described in Sections 4.2, 4.4,
and 4.5. The resulting parameters are then summarized in Section 5. Finally
in Section 6 we put our model to the acid test of predicting (not fitting) the
population neutrophil response in a group of patients undergoing simultaneous
chemotherapy and G-CSF administration [42,43] and obtain excellent agree-
ment between the model predicted behavior and the clinical data. We conclude
with a short discussion in Section 7.
2 Model Summary
Here we define the variables and summarise the equations that define our
granulopoiesis model. A detailed derivation is contained in Section 3. Figure 1
shows a schematic diagram describing the main elements of the hematopoietic
system that we model.
The hematopoietic stem cell (HSC), neutrophil and G-CSF model is a set
of five differential equations including constant and state-dependent delays.
Let Q(t) be the concentration of HSCs at time t, NR(t) be the concentration
of mature neutrophils in the marrow reservoir, and N(t) be the concentration
of the total blood neutrophil pool (TBNP) at time t (which includes both
circulating and marginated neutrophils). Further, let G1(t) be the concentra-
tion of unbound, circulating G-CSF and G2(t) be the concentration of G-CSF
bound to receptors on mature neutrophils (in the reservoir or in the blood
neutrophil pool).
The production of neutrophils from the HSCs is modelled by
d
dtQ(t) = −
(
κ(G1(t)) + κδ + β(Q(t))
)
Q(t)
+AQ(t)β (Q(t− τQ))Q(t− τQ) (1)
d
dtNR(t) = AN (t)κ(G1(t− τN (t)))Q(t− τN (t))
VNM(G1(t))
VNM(G1(t− τNM(t)))
− (γNR + ϕNR(G1(t)))NR(t) (2)
d
dtN(t) = ϕNR(GBF (t))NR(t)− γNN(t), (3)
with the concentrations of G-CSF (unbound and bound to neutrophil G-CSF
receptors) given by
d
dtG1(t) = IG(t) +Gprod − krenG1(t)
− k12([NR(t) +N(t)]V −G2(t))G1(t)Pow+ k21G2(t) (4)
d
dtG2(t) = −kintG2(t) + k12
(
[NR(t)+N(t)]V−G2(t)
)
G1(t)
Pow− k21G2(t), (5)
where IG(t) indicates input of exogenous G-CSF, which we assume is filgrastim
(the most common bio-similar exogenous form of G-CSF). Filgrastim has very
similar PK/PD properties to endogenous G-CSF, so we will not distinguish
between the two types of G-CSF in our model.
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Fig. 1: Schematic representation of the production of circulating neutrophils in
the bone marrow and the interaction of the system with G-CSF. Hematopoi-
etic stem cells (HSCs-Q) enter the neutrophil lineage, the other blood lines, or
are removed from the HSC pool. Differentiated HSCs then undergo successive
divisions during the proliferative phase. Cells then mature before being stored
in the marrow reservoir, or dying off during maturation. Neutrophils remain in
the reservoir until they are removed randomly or enter the circulation, where
they disappear rapidly from the blood. Freely circulating G-CSF may bind
to receptors on the neutrophils. The concentration of bound G-CSF drives
its pharmacodynamic effects. The concentration of G-CSF bound to mature
neutrophils, G2, determines the rate of release from the marrow reservoir. The
concentration of G-CSF bound to neutrophil precursors, assumed proportional
to G1 the concentration of freely circulating G-CSF, determines the rate of
differentiation from the HSCs, the speed of maturation, and the rate of pro-
liferation. For all four effects, speed and rates increase with increasing G-CSF
concentration.
The derivation of these equations is given in Section 3. In Section 3.3,
particular attention is paid to the derivation of the state-dependent delay terms
in (2) from an age-structured partial differential equation (PDE) model of the
mitosis and maturation with variable aging rate of the neutrophil precursors.
The G-CSF equations (4),(5) are explained in detail in Section 3.2.
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In the stem cell equation (1), as explained in Section 3.1, we have
β(Q) = fQ
θs22
θs22 +Q
s2
, (6)
AQ(t) = A
∗
Q = 2e
−γQτQ . (7)
Only in the case of administration of chemotherapy is the stem cell amplifi-
cation factor AQ(t) non-constant. During chemotherapeutic treatment AQ(t)
will be modified by replacing (7) with (38) as discussed in Section 3.5. Stem
cells commit to differentiate to neutrophil precursors at a rate given by
κ(G1) = κ
∗ + (κ∗ − κmin)
[
Gs11 − (G∗1)s1
Gs11 + (G
∗
1)
s1
]
. (8)
Here, and throughout, the superscript ∗ denotes the homeostasis value of a
quantity. The rationale for using (8) to describe the pharmacodynamic effect
of the G-CSF on the differentiation of the HSCs, along with the other G1-
dependent functions is explained in Section 3.4.
After entering the neutrophil lineage, cells undergo mitosis at a variable
rate (ηNP (G1(t))) given by
ηNP (G1(t)) = η
∗
NP + (η
∗
NP − ηminNP )
bNP
G∗1
(
G1(t)−G∗1
G1(t) + bNP
)
(9)
for a proliferation time τNP , considered to be constant. Cells subsequently
mature at a variable aging rate given by
VNM(G1(t)) = 1 + (Vmax − 1)
G1(t)−G∗1
G1(t)−G∗1 + bV
, (10)
until they reach age aNM so the time τNM(t) it takes for a neutrophil maturing
at time t to mature satisfies the integral relationship∫ t
t−τNM(t)
VNM(G1(s))ds = aNM . (11)
At homeostasis, VNM(G
∗
1) = 1, and thus aNM is the homeostatic maturation
time. The total time it takes a neutrophil to be produced (from HSC differen-
tiation to release into the reservoir pool) is
τN (t) = τNP + τNM(t), (12)
and we can differentiate equation (11) to obtain the following DDE for both
τN and τNM
d
dtτN (t) =
d
dtτNM(t) = 1−
VNM(G1(t))
VNM(G1(t− τNM(t)))
. (13)
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Maturing neutrophils are assumed to die at a constant rate given by γNM . The
amplification factor AN (t) between differentiation from HSCs to maturation
that appears in (2) is then given by
AN (t) = exp
[∫ t−τNM(t)
t−τN (t)
ηNP (G1(s))ds− γNM τNM(t)
]
(14)
as derived in Section 3.3. Numerical implementation of the neutrophil amplifi-
cation rate is obtained by differentiating the integral expressions in (14) using
Leibniz’s Rule to obtain
d
dtAN(t) = AN(t)
[(
1− ddtτNM(t)
)(
ηNP (G1(t−τNM(t)))− ηNP (G1(t−τN (t)))
)
− γNM ddtτNM(t)
]
. (15)
After maturation neutrophils are sequestered into the marrow neutrophil reser-
voir. Mature neutrophils exit the reservoir either by dying with constant rate
γNR , or by being released into circulation with a rate ϕNR depending on the
fraction GBF (t) of neutrophil receptors that are bound by G-CSF. We define
GBF (t) =
G2(t)
V [NR(t) +N(t)]
∈ [0, 1], G∗BF =
G∗2
V [N∗R +N∗]
, (16)
and let
ϕNR(GBF (t)) = ϕ
∗
NR + (ϕ
max
NR − ϕ∗NR)
GBF (t)−G∗BF
GBF (t)−G∗BF + bG
. (17)
Neutrophils are removed from circulation with constant rate γN .
In equations (1)–(5) we use units of 109 cells per kilogram (of body mass)
for the reservoir and circulating neutrophils, and 106cell/kg for the stem cells.
The scaling factors ensure that computations are performed with numbers of
similar magnitude which improves numerical stability. Circulating and bound
G-CSF concentrations are measured in standard units of nanograms per millil-
itre of blood. The differing units for neutrophils and G-CSF are only problem-
atical in equations (4),(5) where quantities in both units appear; see Section 4.2
for the derivation of the conversion factor V .
Its also important to note that N(t) measures the total blood neutrophil
pool, including both the circulating and marginated neutrophils. To convert
N(t) to an absolute neutrophil count/circulating neutrophil numbers NC(t)
(or vice versa) there is a conversion factor; see (93).
3 Model Development
Here we describe the development of our granulopoiesis model leading to the
equations presented in Section 2. The equation for the stem cells (1) is de-
scribed briefly in Section 3.1. The size of the mature neutrophil reservoir is
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described by (2). The first term on the right-hand side of this equation gives
the rate that mature neutrophils enter the reservoir. This term is derived from
an age-structured PDE model described in Section 3.3 below. Neutrophils are
assumed to leave the reservoir either by dying at rate γNR or by entering into
circulation at rate ϕNR , and are removed from circulation at a constant rate
γN . In Section 3.2 we describe our new G-CSF model (4),(5) of the unbound
freely circulating G-CSF (G1), and the G-CSF bound to receptors on the neu-
trophils (G2). This model allows us to model the pharmacodynamic effects of
the G-CSF directly as detailed in Section 3.4. Finally, Section 3.5 outlines our
models for the exogenous drugs we will consider in later sections.
3.1 Stem Cells
Equation (1) for the stem cell dynamics was previously used in [35,8,9,45,
20,33,5,11]. In particular, see [4] for a detailed derivation. Here, we remove
the dependence of γQ upon G-CSF as the HSC population is relatively stable
and infrequently dividing [48,16] and, to our knowledge, no direct evidence of
G-CSF’s action upon HSC apoptosis currently exists. Craig [11] uses
AQ(t) = 2 exp
[
−
∫ t
t−τQ
γQ(s)ds
]
, (18)
and in the absence of chemotherapy we take the apoptotic rate γQ to be
constant so this becomes (7).
3.2 A physiologically constructed pharmacokinetic G-CSF model
A new pharmacokinetic model of G-CSF, already stated in (4),(5) is used to
model the concentrations of both unbound and bound G-CSF. We do not dis-
tinguish between endogenous and exogenous G-CSF in the model, which con-
strains us to only consider biosimilar forms of exogenous G-CSF. Accordingly,
we focus on filgrastim, the most widely-available form of exogenous G-CSF.
However, other less common forms of biosimilar exogenous G-CSF are avail-
able and include lenograstim and Nartograstim R© [40]. The pegylated form of
rhG-CSF has greatly reduced renal clearance relative to endogenous G-CSF,
which would require a different model, so we will not consider it in this work.
In equations (4),(5) G1 is the concentration of freely circulating G-CSF
and G2 is the concentration of G-CSF which is bound to receptors on the
neutrophils. Since the bone marrow is well perfused. G-CSF can bind to mature
neutrophils in the marrow reservoir as well as neutrophils in circulation. In
the model kren denotes the nonsaturable removal rate of circulating G-CSF
(mainly renal). kint denotes the removal rate of bound-G-CSF, which we refer
to as the effective internalisation rate. This term models the removal of bound
G-CSF both by internalisation after binding and through the removal of the
neutrophil itself from circulation (along with its bound G-CSF molecules).
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k12 is the rate of binding of free G-CSF to the neutrophils, and Pow is the
effective binding coefficient. The G-CSF receptor has a 2:2 stoichiometry in in
vitro studies [32], so a simple chemical reaction model would suggest Pow =
2. However, the number of ligands binding to a receptor only provides an
upper bound on the corresponding Hill coefficient [51]. Accordingly, we use an
effective binding coefficient Pow ∈ [1, 2].
In this model the bound G-CSF concentration is saturable, with V [NR(t)+
N(t)] being the capacity of this compartment. G2 = V [NR(t) + N(t)] would
indicate that every receptor on every neutrophil in the reservoir and circula-
tion was bound to two G-CSF molecules. Thus the removal rate of neutrophils
by internalisation is saturable. G-CSF also binds to immature neutrophils and
precursors, which will be important for the pharmacodynamics, but since these
cells are fewer in number and/or have fewer receptors than the mature neu-
trophils we neglect this effect on the pharmacokinetics. Finally, k21 is the rate
of unbinding (transformation from bound G-CSF to circulating G-CSF), and
IG(t) denotes exogenous administration of G-CSF, discussed in Section 3.5.
If we were to assume that there is no net transfer between the bound and
circulating G-CSF then letting N˜(t) = [NR(t) +N(t)], equations (4),(5) imply
k12(V N˜(t)−G2)GPow1 − k21G2 ≈ 0. (19)
Rearranging (19) we obtain
G2(t) ≈ [G1(t)]
Pow
[G1(t)]Pow + k21/k12
V N˜(t).
Now, adding (4) and (5)
d
dt (G1 +G2) ≈ IG(t) +Gprod − krenG1 − kintG2,
and assuming that G1  G2 and that ddt (G1 + G2) ≈ ddtG1, and finally
replacing the ≈ by an equality we have
d
dtG1 = IG(t) +Gprod − krenG1 − kintV N˜(t)
[G1(t)]
Pow
[G1(t)]Pow + k21/k12
. (20)
Equations similar to (20) have been used to model G-CSF pharmacokinetics in
many papers including [11,5,20,30,29,69], but usually with N˜(t) = N(t) the
concentration of circulating neutrophils, as opposed to N˜(t) = [NR(t) +N(t)]
as (4),(5) suggest.
The usual derivation of (20) is from the law of mass action, but this is
equivalent to the assumption (19) that the bound and circulating G-CSF are
in quasi-equilibrium. However, the equilibrium hypothesis (19) cannot hold
at homeostasis, since if (19) holds and kint > 0 then
d
dtG2 < 0 which is
contradictory. Clinical evidence [52,64] suggests that at homeostasis, binding
and internalisation is the dominant removal mechanism for G-CSF, so not only
does (19) not hold but the net transfer from unbound to bound G-CSF should
be more than 0.5×Gprod. Another important situation where (19) will fail is
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Fig. 2: Data from Wang [69] for G-CSF concentrations after a 750µg 25 minute
IV infusion and five different simulations: (i) the full neutrophil and G-CSF
model (1)–(5) (ii) the G-CSF only model (68),(69), (iii) the reduced G-CSF
model (20) with kint = 0, (iv) the reduced G-CSF model (20) with kint = 30
and N˜(t) = N(t) and neutrophil concentrations taken from the Wang [69] and
(v) the full neutrophil model (1)–(3) and the reduced G-CSF model (20) with
kint = 25 and N˜(t) = [NR(t) + N(t)]. In ii) Ntot = 4.1457 and G
∗
2 and Gprod
are determined by Equations (74) and (76), respectively. In (ii), (iv) and (v)
kren = 4.12 and Gprod is determined by (20). All other parameters take values
specified in the third columns of Tables 1 and 2.
during exogenous administration of G-CSF, which will initially increase the
concentration of unbound G-CSF (often by orders of magnitude).
Figure 2 illustrates some of the issues involved in modelling the kinetics
of G-CSF. This figure shows data from a 750 µg intravenous (IV) infusion
digitised from Figure 6 of Wang [69], along with a number of simulations of
the protocol using different G-CSF kinetic models. The data in Figure 2 seems
to have at least two different slopes, suggesting that the G-CSF time course
could be approximated by the sum of two exponentials. This naturally leads to
two compartment pharmacokinetic models [15]. Such a two-compartment G-
CSF model was previously considered by Kuwabara [31] for Nartograstim R©.
Consistent with general two-compartment models in pharmacology, the two
compartments corresponded to the blood and the tissues, and generic sat-
urable and nonsaturable removal of the G-CSF both occurred from the blood
compartment. This differs from our model where elimination occurs from the
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two compartments (which instead represent unbound and bound G-CSF con-
centrations), both of which are subject to linear elimination. By contrast, in
our model one compartment is saturable with nonsaturable elimination (the
bound G-CSF), which corresponds to known G-CSF removal mechanisms. The
assignment of elimination to the first or second compartments also has signifi-
cant effects on the estimation of corresponding pharmacokinetic parameters so
the mischaracterisation of these elimination dynamics could have significant
effects on the model’s predictions and behaviours [73].
The circulating G-CSF concentration time course for a simulation of our
full model (1)–(5) tracks the measured G-CSF data very closely in Figure 2.
It slightly overestimates the G-CSF, but it is important to note that the data
points are average values from a number of subjects and we will see in Sec-
tion 4.2 that our G-CSF concentrations are well within the data range for
several of administration protocols.
Also shown in Figure 2 is a simulation of a simplified version of the G-
CSF equations (4),(5) where the time dependent neutrophil term [NR(t) +
N(t)] is replaced by a constant Ntot, so the G-CSF kinetic equations become
independent of the neutrophil dynamics. The resulting equations are stated as
(68),(69) in Section 4.2 where they are used to determine the pharmacokinetic
parameters that appear in (4),(5). The constant Ntot can be thought of as a
time average of the term [NR(t) +N(t)]. As seen in Figure 2, this stand-alone
simplified G-CSF model gives G-CSF concentrations very close to those of the
full model, which justifies using it to determine the kinetic parameters.
Three different simulations of the single G-CSF equation (20) are also
shown in Figure 2 to illustrate the difficulties in dealing with reduced models.
One simulation has kint = 0 so that the elimination of G-CSF is purely renal
and it is clear that the nuances of the G-CSF kinetics are lost.
A simulation of (20) with kint > 0 and N˜(t) = N(t) (with values for N(t)
taken from the Wang data) gives even worse results than the purely renal elim-
ination case. The problem with this model is that for the first few hours while
the neutrophil concentration is low, the elimination of the G-CSF is mainly re-
nal and the solution closely tracks the results from the purely renal elimination
simulation. But as soon as the circulating neutrophil concentrations get high
enough the elimination of G-CSF by binding becomes dominant and quickly
drives the G-CSF concentration to very low levels. Similar results are seen if
our full neutrophil model (1)–(3) is coupled to (20) with N˜(t) = [NR(t)+N(t)].
The tendency of the internalisation term to quickly drive the G-CSF con-
centrations down, along with the propensity for parameter fitting with linear
scales resulted in several previous models using versions of (20) to take kinetic
parameters for which the elimination of G-CSF is always renal dominated.
This is seen both when the G-CSF kinetics is coupled to physiological models
as in [5,11] and when using traditional empirical models as in [69,30], which
consequently all have elimination dynamics which are always renal dominated.
This is true in both the models of Craig [11], which used (20) with N˜(t) =
N(t), and Krzyzanski [30] which used an equation similar to (20) but taking
account of binding to all available receptors. In both, elimination by internal-
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isation is included in the mathematical models but occurs at an insignificant
rate compared to the renal elimination, contrary to the clinical understanding
that elimination of G-CSF by internalisation is the dominant removal mecha-
nism at homeostasis.
From our numerical experiments it seems impossible to fit the single G-
CSF equation (20) to data when N˜(t) is taken to be N(t). The mature marrow
neutrophil reservoir is an order of magnitude larger than the total blood neu-
trophil pool, and the receptors on the mature neutrophils need to be taken into
account in the kinetics as in (4),(5) to obtain a good fit to data. But taking
account of all the receptors is not sufficient to obtain a model that fits the
physiology closely. This is evidenced by the very poor fit obtained in Figure 2
when coupling our neutrophil model to the reduced G-CSF equation (20) with
N˜(t) = [NR(t) + N(t)], and also from models such as that of Krzyzanski [30]
that take account of the G-CSF receptors in marrow, but still obtain renal
dominated kinetics.
The study of congenital diseases like cyclical neutropenia (CN)–an inher-
ently oscillatory and dynamic disease– and exogenous dosing regimens (such
as during chemotherapy) necessitate that the dynamics of G-CSF be well-
characterised. Hence we use the more realistic model (4),(5) for G-CSF phar-
macokinetics rather than the single equation reduction (20).
3.3 Modelling Granulopoiesis
The first term on the right hand side of (2) gives the rate that mature neu-
trophils enter the bone marrow reservoir at time t, and is obtained by modelling
the differentiation of stem cells at time t− τN (t) through mitosis of neutrophil
precursors to time t − τN (t) + τNP = t − τNM(t) followed by maturation of
the cells until time t. The time variation of τN (t) and τNM(t) is solution de-
pendent so this term involves state-dependent delays. Granulopoiesis models
incorporating state-dependent delay have been employed before in [20,19,5],
but the derivation of those models was inaccurate and they missed the impor-
tant VNM(G1(t))/VNM(G1(t−τNM(t))) term. Here we will show in detail how the
mitotic and maturation stages of the neutrophil precursors can be modelled by
age-structured PDE models, whose solution by the method of characteristics
leads to the state-dependent delay terms in (2).
We do not model the cell-cycle process during mitosis, nor do we differ-
entiate between the different maturation stages of dividing cells (myeloblasts,
promyelocytes, myelocytes). Rather, to simplify the modelling and the result-
ing differential equations we model mitosis as an exponential process from
the moment the HSC commits to differentiate to the end of the mitosis. The
proliferation rate ηNP is assumed to be independent of which stage in mitosis
the cell has reached. There is evidence that the cytokine G-CSF affects the
differentiation of HSCs and the effective proliferation rate during mitosis, as
explained in [17], and so we allow both the differentiation rate κ and the prolif-
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Fig. 3: During maturation the aging rate is variable with a˙(t) = VNM(G1(t)), so
age is not trivially related to time, and the maturation time τNM(t) is variable.
eration rate ηNP to vary with G1, the circulating G-CSF, as seen in equations
(8),(9), and explained in Section 3.4.
We let np(t, a) be the cell density as a function of time t and age a during
proliferation. We assume that cells age at a constant rate, a˙ = 1, from age 0
to age τNP , so τNP is also the time period that cells spend in proliferation, and
the proliferation rate is τNP (G1(t)). Then, differentiating,
ηNP (G1(t))np(t, a) =
dnp
dt
=
∂np
∂t
+
da
dt
∂np
∂a
=
∂np
∂t
+
∂np
∂a
so the age-structured PDE model for proliferation is
∂np
∂t
+
∂np
∂a
= ηNP (G1(t))np(t, a), t > 0, a ∈ [0, τNP ], (21)
which, by the method of characteristics has solution
np(t, a) = np(t− a, 0) exp
[∫ t
t−a
ηNP (G1(s))ds
]
, t > 0, a ∈ [0,min{t, τNP }]. (22)
If τNP > a > t > 0 the solution depends on the initial condition np(0, a − t),
but a similar expression applies. Here we have taken homeostasis as the initial
condition throughout and so the solution in (22) is all that is required.
We model the maturing neutrophil precursors (metamyelocytes and bands)
as a single homogeneous compartment. There is evidence that G-CSF affects
the time that cells spend in maturation [63,3] and the speed up in matura-
tion has been measured experimentally [44]. Since the exact mechanism by
which G-CSF affects maturation time is unknown, we will model this pro-
cess by decoupling time from age and demanding that cells age by an amount
aNM , but allowing them to mature at a variable aging rate a˙(t) = VNM(G1(t))
where VNM(G1) is a monotonically increasing function with VNM(0) > 0 and
limG1→∞ VNM(G1) = Vmax <∞.
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Fig. 4: Transition from proliferation to maturation.
See Section 3.4 for further discussion of the function VNM(G1). We assume
that the rate of cell death, γNM , during maturation is constant independent of
the concentration of G-CSF.
We let nm(t, a) be the cell density as a function of time t and age a during
maturation for t > 0 and a ∈ [0, aNM ]. Then the age-structured maturation
model is
∂nm
∂t
+ VNM(G1(t))
∂nm
∂a
=
∂nm
∂t
+
da
dt
∂nm
∂a
=
dnm
dt
= −γNMnm(t, a). (23)
The characteristics are defined by a˙ = VNM(G1(t)), and along characteristics
for t > τNM(t) we obtain
nm(t, aNM ) = nm(t− τNM(t), 0)e−γNM τNM(t). (24)
Age-structured PDE models have been used in hematopoiesis models many
times previously [33,20,9,11], but special care needs to be taken to interpret
nm(t, a) when the maturation has variable velocity, or an incorrect solution
will be obtained.
Cells which mature at time t enter maturation at time t − τNM(t) and so
differentiated from HSCs at time t − τNM(t) − τNP = t − τN (t). The rate at
which cells differentiate at time t− τN (t) is κ(G1(t− τN (t)))Q(t− τN (t)), and
hence
np(t− τN (t), 0) = κ(G1(t− τN (t)))Q(t− τN (t)).
Then by (22)
np(t−τNM(t), aNM ) = np(t− τN (t), 0) exp
[∫ t
t−aNM
ηNP (G1(s))ds
]
= κ(G1(t− τN (t)))Q(t− τN (t)) exp
[∫ t
t−aNM
ηNP (G1(s))ds
]
. (25)
To obtain the boundary condition for the maturation phase, note that
np(t, τNP ) is the rate at which cells leave proliferation and enter maturation.
Hence, to leading order, np(t, τNP )δt cells enter maturation in the time in-
terval [t, t + δt]. Cells that enter maturation at time t will already have age
VNM(G1(t))δt by time t + δt. Since np(t, a) and nm(t, a) describe the density
of cells in the proliferation and maturation phases, to avoid the spontaneous
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creation or destruction of cells at the transition between proliferation and
maturation we require∫ VNM(G1(t))δt
0
nm(t+ δt, a)da−
∫ t+δt
t
np(t, τNP )dt = O(δt2).
Then
VNM(G1(t))nm(t, 0) = lim
δt→0
1
δt
∫ VNM(G1(t))δt
0
nm(t+ δt, a)da
= lim
δt→0
1
δt
∫ t+δt
t
np(t, τNP )dt = np(t, τNP ), (26)
and hence the boundary condition for the maturation compartment is
nm(t− τNM(t), 0) = np(t− τNM(t), τNP )/VNM(G1(t− τNM(t))). (27)
Combining (24), (25), (27) and (14) we obtain
nm(t,aNM ) =
np(t− τNM(t), τNP )
VNM(G1(t− τNM(t)))
e−γNM τNM(t)
=
κ(G1(t− τN (t))Q(t− τN (t))
VNM(G1(t− τNM(t)))
exp
[∫ t−τNM(t)
t−τN (t)
ηNP (G1(s))ds− γNM τNM(t)
]
=
κ(G1(t− τN (t)))Q(t− τN (t))
VNM(G1(t− τNM(t)))
AN (t). (28)
Again because of the variable aging-rate there is a correction factor to apply
to nm(t, aNM ) to obtain the rate that cells leave maturation. To calculate
this rate notice that cells which reach age aNM at time t have age aNM −
VNM(G1(t))δt + O(δt2) at time t − δt. Thus the number of neutrophils that
mature in the time interval [t− δt, t] is
aNM∫
aNM−VNM(G1(t))δt
nm(t− δt, a)da+O(δt2) = VNM(G1(t))nm(t, aNM )δt+O(δt2).
Hence, the rate that cells leave maturation is VNM(G1(t))nm(t, aNM ), which
using (28) can be written as
κ(G1(t− τN (t)))Q(t− τN (t))AN (t) VNM(G1(t))
VNM(G1(t− τNM(t)))
, (29)
which is the first term on the right-hand side of (2). The correction factor
VNM(G1(t))/VNM(G1(t− τNM(t))) was omitted from the state-dependent DDE
models in [20,5].
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3.4 G-CSF Pharmacodynamics
G-CSF in concert with many other cytokines regulates important parts of
granulopoiesis. The precise mechanisms by which it does this are not fully
understood (and would probably be beyond the level of detail that we would
want to model mathematically even if they were) but it is known that G-CSF
acts along several signalling pathways in complex processes which activate and
generate secondary signals that regulate neutrophil production [23,59,70].
The initiation of signalling pathways and the transfer of the resulting sig-
nals responsible for the various effects of a given drug may be driven directly
by receptor binding and/or the internalisation of the drug. Assuming the rate
at which a drug is internalised is proportional to its bound concentration, we
do not need to distinguish between the different possible pathways and will
use the concentration of the bound drug to drive the pharmacodynamics and
produce the effects in the body.
Many previous models applied the cytokine paradigm mentioned in the
introduction to model cytokine effects directly from the circulating neutrophil
concentrations. For example in [8,9,20,33,5,11], the differentiation function
was taken to be a monotonically decreasing function of the circulating neu-
trophil concentration. Some authors preferred instead to introduce simplified
pharmacodynamic models using direct and indirect PD effects related to the
concentration of unbound G-CSF [69,60] while other more detailed approaches
have also been studied [58,66,65].
The cytokine paradigm breaks down when G-CSF is given exogenously.
Immediate responses of the hematopoietic system to G-CSF administration
include releasing neutrophils from the marrow reservoir into circulation, and
increasing the maturation speed of neutrophils, so the circulating concentra-
tion of neutrophils and the total number of neutrophils in the reservoir and
circulation both increase, which results in G-CSF and neutrophil concentra-
tions being high concurrently. Consequently we will use G-CSF concentrations
from (4),(5) to directly model the pharmacodynamic effects of G-CSF on the
differentiation rate of HSCs κ, the effective proliferation rate of neutrophil
precursors in mitosis ηNP , the aging rate of maturing neutrophils VNM, and the
release rate of neutrophils from the bone marrow reservoir ϕNR .
We use Hill and Michaelis-Menten functions to model the G-CSF depen-
dency of these effects. There is some disagreement in the literature over exactly
which cytokines are important in different parts of the process, and we may be
assigning some effects to G-CSF that are actually due to GM-CSF or one of the
other myriad of cytokines that regulate granulopoiesis. If these other cytokines
are mostly in quasi-equilibrium with G-CSF, using G-CSF as a cipher for all
the cytokines should produce very similar effects without the extraordinary
complexity that would be inherent in modelling each one of the cytokines.
Mammalian studies [24,6,34] reveal that neutrophils are still produced even
in the absence of G-CSF, presumably because other cytokines are acting. Ac-
cordingly, we will construct our effects functions to have non-zero activity
even in the complete absence of G-CSF. Moreover, in Section 4.3 we will con-
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sider the case of G-CSF knockout mathematically with our model to derive a
parameter constraint to reduce the number of unknown parameters.
Recall that the concentration of G-CSF bound to mature neutrophils satis-
fies the inequality G2(t) 6 V [NR(t) +N(t)] with equality only if every G-CSF
receptor were bound to two G-CSF molecules. We suppose that the rate that
mature neutrophils are released from the marrow reservoir into circulation is
dependent on the fraction GBF (t) = G2(t)/(V [NR(t)+N(t)]) of their receptors
which are bound to G-CSF. The rate is then given by the Michaelis-Menten
function ϕNR(G1) defined by (17). Letting
ϕratioNR =
ϕmaxNR
ϕ∗NR
> 1, (30)
this function is also similar to the one used by Shochat [60] that was adapted
in Craig [11] except that we use the fraction of bound receptors to drive the
function. At homeostasis (16) and (17) imply that
ϕNR(G
∗
BF ) = ϕNR(G
∗
2/[V (N
∗ +N∗R)]) = ϕ
∗
NR .
The parameter bG defines the half-effect concentration with
ϕNR(G
∗
BF + bG) =
1
2
(ϕ∗NR + ϕ
max
NR ),
while the condition ϕNR(0) > 0 implies the constraint
bG > ϕ
ratio
NR G
∗
BF =
G∗2ϕ
ratio
NR
V (N∗R +N∗)
. (31)
To model the effects of G-CSF on the differentiation, proliferation and mat-
uration some care must be taken. We posit that it is cytokine signalling that
drives these processes, and G2(t) denotes the concentration of bound G-CSF,
which is proportional to the rate that G-CSF is internalised. So it would be
tempting to use G2(t) to govern these processes, and indeed initially we tried
this without success. The problem is that G2(t) models the concentration of
G-CSF bound to mature neutrophils in the marrow reservoir and circulation.
Through (4) and (5) this gives a very good model of the removal of G-CSF
from circulation because although the neutrophil progenitor cells also have
G-CSF receptors, these cells are relatively few in number and have relatively
few receptors, hence they can be ignored when modelling the G-CSF kinetics.
However, when modelling the pharmacodynamic effects of G-CSF it appears
to be crucial to take account of the binding of G-CSF to the neutrophil pre-
cursors, and it is the freely circulating G-CSF which is available to bind to the
G-CSF receptors on the immature neutrophils and precursors. Consequently,
we should use G1(t) to govern the cytokine dependent differentiation, prolif-
eration, and maturation.
Another way to see that it should be the circulating G-CSF G1(t), and
not the G-CSF bound to mature neutrophils G2(t) that should govern these
processes is as follows. If the concentration of mature neutrophils is decreased
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then the concentration of bound G-CSF will also decrease because the number
of receptors available to bind to will be decreased, but the concentration of
unbound G-CSF will increase because the rate the G-CSF is removed by inter-
nalisation is reduced. However, with a reduced concentration of neutrophils,
an elevated cytokine concentration is needed to increase differentiation, pro-
liferation and maturation speed.
We model the differentiation rate from HSCs to neutrophil precursors using
the Hill function (8). Very little is known about how the differentiation rate
changes in function of G-CSF, but we suppose that it will not vary by orders
of magnitude, since this would lead to instability in the HSC population, while
the HSC population is observed to be very stable in healthy subjects [48]. It
is then convenient to assume that the homeostatic rate is at the midpoint of
the range of possible differentiation rates so
κ∗ =
1
2
(κmin + κmax). (32)
With this assumption (8) is a standard sigmoidal Hill function with minimum
differentiation rate κ(0) = κmin, and with κ(G1) increasing monotonically with
G1 and such that at homeostasis κ(G
∗
1) = κ
∗, while for large concentrations
limG1→∞ κ(G1) = κ
∗+(κ∗−κmin) = κmax. To ensure that neutrophils are still
produced in the complete absence of G-CSF we will require that κmin > 0.
G-CSF is believed to increase the effective rate of mitosis during prolifera-
tion by reducing apoptosis. Thus we use a monotonically increasing Michaelis-
Menten function ηNP (G1(t)) defined by (9) to describe the G-CSF depen-
dent effective proliferation rate (which measures the difference between ac-
tual proliferation and apoptosis). This function looks a little different than
the other Michaelis-Menten functions we will use, but this is simply because
it has been scaled to give the correct minimal and homeostasis effects with
ηNP (0) = η
min
NP
> 0 and ηNP (G
∗
1) = η
∗
NP
, with ηNP (G1) a monotonically in-
creasing function of G1.
Letting
ηmaxNP = limG1→∞
ηNP (G1) = η
∗
NP +
bNP
G∗1
(η∗NP − ηminNP ),
we see that
bNP
G∗1
=
ηmaxNP − η∗NP
η∗NP − ηminNP
,
so the parameter bNP > 0 determines the relative position of η
∗
NP
∈ [ηminNP , ηmaxNP ]
with η∗NP > (η
min
NP
+ ηmaxNP )/2 when bNP ∈ (0, G∗1) and η∗NP < (ηminNP + ηmaxNP )/2
when bNP > G
∗
1.
G-CSF is known to affect the time that neutrophils spend in maturation
[63,3], an acceleration in maturation that Price [44] measured experimentally,
but the mechanism by which G-CSF speeds up maturation is not well un-
derstood. We choose to model this process by decoupling time from age and
demanding that cells age by an amount aNM , but allowing them to mature
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at a variable aging rate a˙(t) = VNM(G1(t)) where VNM(G1) is a monotonically
increasing Michaelis-Menten function given in (10). This is similar to the form
used in Craig [11] which was adopted from Foley [20], and is also functionally
equivalent to (17).
bV is the half effect parameter for the aging velocity with VNM(G
∗
1 + bV ) =
(1 + Vmax)/2. We require that VNM(0) > 0, which from (10) is equivalent to
bV > G
∗
1Vmax. (33)
This constraint ensures that the aging velocity VNM(G1) is strictly positive for
all G1 > 0. The function VNM(G1) also satisfies the homeostasis condition
VNM(G
∗
1) = 1, so that at homeostasis the aging rate is 1. The aging rate
saturates with limG1→∞ VNM(G1) = Vmax <∞.
Notice that, using (13)
d
dt (t− τNM(t)) = 1− ddtτNM(t) =
VNM(G1(t))
VNM(G1(t− τNM(t)))
, (34)
and positivity of VNM(G1) assures that t− τNM(t), and similarly t− τN (t), are
monotonically increasing functions of t. This is important in state-dependent
DDE theory for existence and uniqueness of solutions. Physiologically, it as-
sures that cells which have exited proliferation or maturation never re-enter
those phases.
The responses of our new model and the model of Craig [11] to exogenous
administration of G-CSF are very different. With our new model both differ-
entiation and proliferation are increased with increased G-CSF so that after
some time delay the marrow reservoir gets replenished. In the previous model,
the G-CSF triggered an immediate release of neutrophils from the marrow
reservoir into circulation and the resulting high circulating neutrophil count
would cause differentiation and proliferation to be decreased. This meant the
the marrow reservoir would suffer a double depletion with increased release
into circulation combined with reduced production of new mature neutrophils,
which could lead to instabilities in the model that ought not to be occurring
in the granulopoiesis of healthy subjects.
Since the four functions (8),(9),(10) and (17) describe the effects of G-
CSF on granulopoiesis, rather than modelling the processes that lead to the
effects, the parameters in these functions do not correspond to physiological
quantities that can be measured directly. Nevertheless these parameters can
be determined by fitting the response of the system to experimental data as
described in Section 4.4.
3.5 Modelling exogenous drug administration
As noted following (4), IG(t) denotes the input of exogenous G-CSF. The
administration of rhG-CSF (in our case filgrastim) typically takes two forms:
IV infusion (where the drug is given intravenously over a period of time)
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or subcutaneously (injection under the skin). In the former case, the drug
passes directly into the bloodstream meaning the bioavailable fraction (the
percentage of the administered dose that enters the blood) is 100%. In this
case, we express the single exogenous administration as
IG(t) =
{
Do
tinfVd
, t0 6 t 6 tinf
0 otherwise,
(35)
where Do is the administered dose, t0 is the start of the infusion, tinf is the time
of infusion and Vd is the volume of distribution. The volume of distribution
is a pharmacokinetic parameter which relates the hypothetical volume a drug
would occupy to the concentration it is observed in the plasma. It is typically
calculated for a drug by dividing the administered dose by the concentration
in the blood immediately following an administration for the simplest case of
IV bolus administration (instantaneous administration into the blood). Drugs
given subcutaneously do not immediately reach the bloodstream. Instead, a
certain proportion of the medication remains in the subcutaneous tissue pool
before diffusing into the plasma. Some previous studies, notably [20,5] used an
extra transition compartment to model the administered G-CSF concentration
in the tissues before reaching the blood and allowed for the free exchange
between this central (blood) compartment and the tissue compartment. Owing
to the specifics of the pharmacokinetics of filgrastim, we will instead use the
following direct input functions from [30] and [11] to model subcutaneous
administration as
IG(t) =
{
kaDoF
Vd
ekat, t > t0
0 t < t0,
(36)
where ka is the constant of absorption, and F is the bioavailable fraction (the
fraction of non-metabolised dose which enters the system). This direct form
is preferred over the two compartment method previously employed in [20,5]
because of the relatively small volume of distribution exhibited by filgrastim
(the bio-similar exogenous form of G-CSF), which is to say that Vd is less than
the standard 70L measure of highly distributed drugs [11] and that the drug
does not have a strong tendency to redistribute into the tissues.
The pharmacokinetic model of the chemotherapeutic drug (Zalypsis R©)
used in this paper is the same as in [11]. Briefly, the concentration of chemother-
apeutic drug in the system is modelled using a set of four ordinary differential
equations which was determined to be suitable through population pharma-
cokinetic analysis [41]. The PK model of Zalypsis R© is given by
d
dtCp(t) = IC(t) + kfpCf (t) + ksl1pCsl1(t)− (kpf + kpsl1 + kelC )Cp(t)
d
dtCf (t) = kpfCp(t) + ksl2fCsl2(t)− (kfp + kfsl2)Cf (t) (37)
d
dtCsl1(t) = kpsl1Cp(t)− ksl1pCsl1(t), ddtCsl2(t) = kfsl2Cf (t)− ksl2fCsl2(t),
where Cp is the concentration in the central (blood) compartment, Cf is the
concentration in the fast-exchange tissues, and Csl1 and Csl2 are the concen-
trations in the slow-exchange tissues, kij are traditional rate constants between
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the ith and jth compartments (i, j = p, f, sl1, sl2), and kelC is the rate of elimi-
nation from the central compartment. We consider the chemotherapeutic drug
to be administered by IV infusion, so IC(t) = DoseZal/∆t, where DoseZal is
the administered dose and ∆t is the time of infusion.
In contrast to the pharmacodynamic effects of G-CSF, chemotherapy has
negative effects on the neutrophil (and other blood) lineages. Chemotherapy
(and radiotherapy) works by disrupting the cell-cycle of tumours [37] but this
interference also affects all cells which are dividing, including the neutrophil
progenitors. The cytotoxic side effects chemotherapeutic treatment has on the
neutrophils is called myelosuppression and it is a leading cause of treatment
adaptation and/or cessation for patients undergoing chemotherapy [11]. Since
chemotherapy’s myelosuppressive action only affects cells capable of division,
we model the pharmacodynamic effects of chemotherapy on the HSCs, which
rarely divide, and the neutrophil progenitors in the proliferative phase, which
divide regularly until they exit the mitotic phase.
Since the effects of chemotherapy on the HSCs are not clear, we model
the antiproliferative effect as a simple linear decrease of the rate of apoptosis
experienced by these cells by replacing γQ in equation (18) by γQ + hQCp(t)
where Cp(t) is the concentration of the chemotherapeutic drug in the central
blood compartment given by (37), and hQ is a factor to be determined (as
outlined in Section 4.5). Then (18) gives
AQ(t) = 2e
−γQτQ−hQ
∫ t
t−τQ Cp(s)ds. (38)
It is convenient to numerically implement (38) as a differential equation, and
applying Leibniz’s Rule to (38), similar to the derivation of (15), we obtain
d
dtAQ(t) = (hQ(Cp(t− τQ)− Cp(t)))AQ(t), (39)
and we replace (7) by (39) when chemotherapy is administered.
The second effect of chemotherapeutic drugs is to reduce the effective pro-
liferation rate of the mitotic neutrophil progenitors. We model this by replacing
ηNP of (9) by
ηchemoNP (G1(t), Cp(t)) = η
inf
NP
+
ηNP (G1(t))− ηinfNP
1 + (Cp(t)/EC50)sc
, (40)
which is a modification of the model used in [11]. Here ηinfNP corresponds to
the effective proliferation rate in the presence of an infinite dose of the drug.
We require ηinfNP < η
min
NP
to ensure that effective proliferation is reduced, so
ηchemoNP (G1(t), Cp(t)) < η
chemo
NP
(G1(t)) whenever Cp(t) > 0. We will allow the
possibility of ηinfNP < 0, which would correspond to negative effective prolif-
eration (more death than division in the mitotic phase) in the presence of
very large concentrations of the chemotherapeutic drug, though we note that
because the drug is cleared from circulation relatively quickly we will have
ηchemoNP (G1(t), Cp(t)) > 0 most of the time even if η
inf
NP
< 0. If ηinfNP ∈ (0, ηminNP )
then effective cell division is reduced but never completely halted however large
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the concentration of the chemotherapeutic drug. EC50 is the concentration of
chemotherapeutic drug which gives the half-maximal effect, and sc is a Hill
coefficient. The parameters hQ, η
inf
NP
, EC50, and sc will all be estimated using
fitting techniques described in Section 4.5.
4 Parameter Estimation and Equation Constraints
In this section we show how our mathematical model imposes constraints on its
own parameters to be self-consistent, and how experimental data can be used
to determine model parameters. We begin in Section 4.1 by studying the model
at homeostasis and deriving inequalities that the parameters must satisfy, as
well as showing how experimentally measured quantities can be used to directly
determine some parameters in the model. In Section 4.2 we show how the G-
CSF pharmacokinetic parameters can be determined using a combination of
model equation constraints and parameter fitting to experimental data from
single administrations of G-CSF. In Section 4.3, G-CSF knockout is used to
derive further parameter constraints and relationships. Finally in Section 4.4
we show how the pharmacodynamic parameters in the neutrophil equations
can be determined by fitting the model to experimental data for the circulating
neutrophil concentrations after a single IV or subcutaneous administration of
G-CSF.
4.1 Neutrophil Steady-State Parameter Determination and Constraints
At homeostasis let Q∗ be the stem cell concentration and denote the sizes of
the four neutrophil compartments at homeostasis by N∗P (proliferation) , N
∗
M
(maturation), N∗R (marrow reservoir), N
∗ (total blood neutrophil pool), and
the average time that a cell spends in one of these stages at homeostasis by
τNP , aNM , τ
∗
NR
and τ∗NC , respectively. With the exception of τNP , all of these
quantities have been determined experimentally, but unfortunately only τNP
and aNM actually appear in our model. In this section we show that our model
imposes some constraints on the values of these parameters, and also how the
values of κ∗, N∗P , N
∗
M , N
∗
R, N
∗, aNM , τ
∗
NR
and τ∗NC can be used through the
model to determine values for the parameters τNP , η
∗
NP
, γNM , γNR , γN and
ϕ∗NR which do appear in the model in Section 2.
At homeostasis equations (1)–(3) become
0 = −(κ∗ + κδ + β(Q∗))Q∗ +A∗Qβ(Q∗)Q∗, (41)
κ∗Q∗A∗N = (ϕ
∗
NR + γNR)N
∗
R, (42)
ϕ∗NRN
∗
R = γNN
∗. (43)
Equation (41) has the trivial solution Q∗ = 0 with other solutions given by
κ∗ + κδ = (A∗Q − 1)β(Q∗) (44)
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To the best of our knowledge, there is no experimental data to determine the
relative rates of differentiation to the three cell lines (erythrocytes, neutrophils,
thrombocytes) at homeostasis. In the absence of any evidence to the contrary,
we will assume that these are all equal. Since κ∗ denotes the differentiation rate
to the neutrophil line and κδ differentiation to erythrocyte and thrombocyte
precursors we obtain
κ∗ = 12κδ =
1
3 (A
∗
Q − 1)β(Q∗). (45)
At homeostasis neutrophil precursors are assumed to enter the mitotic
phase at rate κ∗Q∗. They then proliferate at a rate η∗NP for a time τNP . The
total number of cells in the proliferative phase at homeostasis is thus
N∗P =
∫ τNP
0
κ∗Q∗eη
∗
NP
sds = κ∗Q∗
eη
∗
NP
τNP − 1
η∗NP
, (46)
and cells leave proliferation and enter maturation at a rate R∗P given by
R∗P = κ
∗Q∗eη
∗
NP
τNP . (47)
At homeostasis from (10) we have VNM(G
∗
2) = 1, and thus from (11), the
time spent in maturation at homeostasis is aNM . The number of cells of age
s for s ∈ [0, aNM ] in the maturation phase is then κ∗Q∗ exp(η∗NP τNP − γNM s),
and the total number of cells in the maturation phase is
N∗M =
∫ aNM
0
κ∗Q∗eη
∗
NP
τNP−γNM sds = κ∗Q∗eη
∗
NP
τNP
1− e−γNM aNM
γNM
. (48)
Writing
A∗N = exp
(
η∗NP τNP − γNMaNM
)
, (49)
which corresponds to (14) at homeostasis, we can rewrite (48) as
N∗M = κ
∗Q∗A∗N
eγNM aNM − 1
γNM
. (50)
Now the rate at which cells leave the maturation phase is
κ∗Q∗eη
∗
NP
τNP−γNM aNM = κ∗Q∗A∗N .
The average time, τ∗NC , that neutrophils spend in circulation in the blood
(in the total blood neutrophil pool) has been measured a number of times.
However, what is actually measured is the half removal time, τ1/2, which gives
γN , the removal rate from circulation by
γN =
1
τ∗NC
=
ln 2
τ1/2
. (51)
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Equation (43) ensures that at homeostasis the rate neutrophils leave the
reservoir and enter circulation equals the rate at which they are removed from
circulation. From this we obtain
ϕ∗NR =
γNN
∗
N∗R
. (52)
The rate at which neutrophils exit the mature marrow reservoir is given
by (ϕ∗NR + γNR)N
∗
R where ϕ
∗
NR
is the transition rate constant for cells entering
circulation and γNR is the random death rate. Thus the average time that cells
spend in the reservoir at homeostasis is
τ∗NR =
1
ϕ∗NR + γNR
. (53)
Hence the random death rate in the reservoir, γNR > 0, is given by
γNR =
1
τ∗NR
− ϕ∗NR , (54)
and we require that
τ∗NRϕ
∗
NR 6 1 (55)
to ensure that γNR > 0. That said, using (51) and (52), we can rewrite (55) as
τ∗NR
τ∗NC
6 N
∗
R
N∗
. (56)
The apoptosis rate during the maturation phase, γNM > 0, is calculated by
eliminating κ∗Q∗A∗N from (42) and (50). Also making use of (54), we obtain
FM (γNM ) := N
∗
R(e
γNM aNM − 1)− γNM τ∗NRN∗M = 0. (57)
It is easy to see that FM (0) = 0 and hence γNM = 0 is one solution of (57).
Since F ′′M (γ) > 0 for all γ > 0, if F ′M (0) < 0 there is a unique γNM > 0 such that
FM (γNM ) = 0, and no positive value of γ such that FM (γ) = 0 if F
′
M (0) > 0.
Since cell death is known to occur in the maturation compartment (see [36]),
we should choose our parameters so that (57) admits a solution γNM > 0. The
condition F ′M (0) > 0 is equivalent to
N∗R
N∗M
<
τ∗NR
aNM
, (58)
and to include apoptosis in the maturation compartment our parameters must
be chosen to satisfy (58).
Equation (56) can be interpreted as a lower bound on τ∗NR , and (58) as
an upper bound. Eliminating τ∗NR from these two bounds we find that the
parameters must satisfy
aNM
τ∗NC
<
N∗M
N∗
(59)
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for the constraints (56) and (58) to be consistent. Then τ∗NR must satisfy
τ∗NR ∈
(
aNM
N∗R
N∗M
, τ∗NC
N∗R
N∗
)
(60)
for both (56) and (58) to be satisfied as strict inequalities. All the quantities
in (60) have been estimated experimentally. To be consistent with our model
the values must satisfy both (59) and (60). In Section 5 we state parameters
that satisfy these constraints. With those parameters we take γNM > 0 to be
the unique strictly positive solution to (57).
Equation (42) ensures that the rate cells enter and leave the reservoir are
equal at homeostasis. Rearranging and using (52) we obtain
A∗N =
N∗R
κ∗Q∗τ∗NR
, (61)
which determines A∗N . Now from (49) we have
eη
∗
NP
τNP = A∗Ne
γNM aNM , (62)
which determines eη
∗
NP
τNP , and it remains to determine one of η∗NP or τNP in
order to be able to find the other. However (46) implies that
η∗NP = κ
∗Q∗
eη
∗
NP
τNP − 1
N∗P
= κ∗Q∗
A∗Ne
γNM aNM − 1
N∗P
(63)
and now from (62) we have
τNP =
1
η∗NP
ln
(
A∗Ne
γNM aNM
)
. (64)
In Section 5 we use the equations of this section to determine parameter values
for our model.
4.2 Estimation of G-CSF Pharmacokinetic Parameters
Following [71,26,2,30] we take the homeostasis concentration of the free cir-
culating G-CSF to be G∗1 = 0.025 ng/mL. The parameter V in (5) is the same
parameter V as appears in (20). But V is difficult to interpret directly from
(20), and although published values are available, they vary widely between
sources. For the pharmacokinetic G-CSF model (4),(5) the meaning of V is
clear; its simply the conversion factor that converts a neutrophil concentra-
tion N in units of 109 cells per kilogram of body mass, into the corresponding
G-CSF concentration V N in units of nanograms per millilitre when every
receptor on the neutrophils is bound.
To compute V , we first note that the molecular mass of G-CSF is 18.8 kDa =
18800 g/mol [30] or dividing by Avogadro’s constant, the equivalent weight of
G-CSF is Gmw = 3.12× 10−11 ng/molecule. We take the number of receptors
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per neutrophil to be R = 600, which is in the middle of the range that Barreda
[2] cites, though we note that both smaller and larger numbers can be found
in the literature. Then given N , the number of receptors per millilitre is
R× 70
5000
× 109 ×N,
where we assume body mass of 70 kg and 5000 mL of blood. Since two molecules
bind to each receptor the maximum concentration of bound G-CSF is
V N = 2×Gmw ×R× 70
5000
× 109 ×N = 0.525N ng/mL
and hence
V = 0.525 (ng/mL)/(109cells/kg). (65)
Values have been published for several of the other parameters in the
G-CSF equations (4),(5), but these have been largely based on in vitro ex-
periments and/or simpler G-CSF models using mixed-effects estimation tech-
niques, and so are not directly applicable to our model [30,69,58,52].
At homeostasis, equations (4),(5) give
G∗2 =
(G∗1)
Pow
(G∗1)Pow + (kint + k21)/k12
V [N∗R +N
∗], (66)
and
Gprod = krenG
∗
1 + kintG
∗
2
= krenG
∗
1 + kintV [N
∗
R +N
∗]
(G∗1)
Pow
(G∗1)Pow + (kint + k21)/k12
. (67)
Once values of kint, k12, k21, kren and Pow are determined as we describe
below, (66) and (67) determine values for G∗2 and Gprod.
The remaining parameters might be determined by simulating the full
model with exogenous G-CSF administration and fitting the response of the
model to published data for such experiments. However, that would involve
also fitting the as yet undetermined pharmacodynamic parameters in equa-
tions (1)–(17) which would create a very large optimisation problem, with the
potential for interactions between the pharmacokinetic and pharmacodynamic
parameters to create a complicated functional with many local minima. To
avoid this, we prefer to determine the pharmacokinetic and pharmacodynamic
parameters separately. Here we determine the PK parameters by decoupling
the G-CSF equations (4)-(5) from the neutrophil dynamics.
There have been a number of studies tracking the response of the hematopoi-
etic system to a single administration of exogenous G-CSF including Wang [69]
and Krzyzanski [30]. If data were available for circulating neutrophil and mar-
row reservoir neutrophil concentrations as functions of time it would be possi-
ble to treat equations (4)-(5) separately from the rest of the model as a system
of two ordinary differential equations with [NR(t) +N(t)] treated as a known
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non-autonomous forcing term determined by the data. But unfortunately it
is not known how to directly measure either marrow neutrophil reservoir or
bound G-CSF concentrations, and such values are not reported in the litera-
ture.
In the absence of marrow neutrophil data we will decouple the G-CSF
kinetic equations (4)-(5) from the rest of the model by replacing the time
dependent term [NR(t) +N(t)] by the constant Ntot to obtain
d
dtG1(t) = IG(t) +Gprod − krenG1(t)
− k12(NtotV −G2(t))G1(t)Pow + k21G2(t) (68)
d
dtG2(t) = −kintG2(t) + k12
(
NtotV−G2(t)
)
G1(t)
Pow − k21G2(t). (69)
In (68) and (69) the constant Ntot represents the constant total number of neu-
trophils available for G-CSF binding, and will be treated as an extra parameter
to be determined during the fitting. It should correspond approximately to an
average value of [NR(t) +N(t)] across the time course of the data.
With data for bound G-CSF unavailable we are constrained to fit (68),(69)
to data for the unbound G-CSF. To do this we use digitisations of two sets of
data from Wang [69] from a 750µg intravenous (IV) administration of G-CSF
and from a subcutaneous (SC) administration of the same dose. SC adminis-
trations necessarily include the absorption kinetics of a drug, as outlined in
equation (36), whereas IV administrations reach the blood directly and can
be modelled more simply as in (35). For these reasons, both IV and SC data
were used simultaneously during the fitting procedure to best characterise the
parameters. Rather than fitting directly to the data from Wang [69], to obtain
robust parameter fits we took the G-CSF data from the SC and IV adminis-
trations and fit a spline through each to define functions GSCdat(t) and G
IV
dat(t)
over the time intervals 0 6 t 6 2 days for which the data were taken. With
postulated parameter values we then use the Matlab [38] ordinary differen-
tial equation solver ode45 to simulate (68),(69) over the same time interval
to define functions GSC1 (t) and G
IV
1 (t). We measure the error between the
simulated solutions and the data using the L2 function norm defined by
‖G‖22 =
∫ T
0
G(t)2dt. (70)
For the IV data which varies over orders of magnitude, as seen in Figure 2, we
use a log scale, while for the SC data a linear scale is appropriate. We define
a combined error function for both simulations by
Err = ‖ log(GIV1 )− log(GIVdat)‖22 + χ0.95‖GSC1 −GSCdat‖22, (71)
where the scale factor χ defined by
χ =
maxt∈[0,T ] log(GIVdat(t))−mint∈[0,T ] log(GIVdat(t))
maxt∈[0,T ]GSCdat(t)−mint∈[0,T ]GSCdat(t)
, (72)
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effectively rescales the data so that both data sets have equal weight. (Since
χ < 1 the power 0.95 in (71) works to give slightly more weight to the SC
data).
Fitting was performed using the Matlab [38] lsqcurvefit least squares solver,
with the error function Err evaluated numerically by sampling the functions
at a thousand equally spaced points. It is convenient to define the constant
Nelim = 1− krenG
∗
1
Gprod
(73)
where Nelim is the fraction of G-CSF clearance performed through internal-
isation at homeostasis (obtained in (73) as one minus the fraction of renal
clearance at homeostasis). The estimation was performed for the G-CSF pa-
rameters: k12, k21, Pow, kint, the neutrophil constant Nelim, and the phar-
macokinetic drug parameters ka, and F . The elimination fraction Nelim was
either fixed (Nelim = 0.6 and 0.8 in Table 1) or fitted (the other entries in Ta-
ble 1). At each step of the optimisation the candidate k12, k21, Pow, kint and
Nelim are used to determine the dependent parameters G
∗
2, kren, and Gprod,
which from (68),(69) and (73) are given by
G∗2 = V Ntot
(G∗1)
Pow
(G∗1)Pow + (k21 + kint)/k12
(74)
kren =
(
−1 + 1
Nelim
)
V kint(G
∗
1)
(Pow−1) Ntot
(G∗1)Pow + (k21 + kint)/k12
(75)
Gprod = kintG
∗
2 + krenG
∗
1. (76)
The following fitting procedure was employed. First parameters were fit
from IV data for a 750µg administration [69] on the log scale to ensure that
behaviour at both high and low concentrations were properly characterised.
Next initial SC parameters were fit from 750µg SC data in linear scale. Us-
ing the parameters from these two fits as seed values, we next obtain final
parameter values by fitting both log-concentration IV and linear SC data si-
multaneously using the norm defined in (71). Finally, as the pharmacokinetic
parameters related to the SC administration have been shown to be dose-
dependent [58], we re-estimate F and ka for lower doses of 300µg and 375µg
[30,69]. Since Vd is typically calculated by the ratio of the dose to the ini-
tial concentration in the blood for IV administrations [15], we have applied
the same calculation here to scale the G-CSF prediction to the first measured
data point. Accordingly, the volume of distribution was recalculated to fit the
administered dose. The resulting parameters are reported in Table 1.
Figure 5 compares the solutions from the fitting procedure of the simplified
model (68) (69) for the parameter set with Nelim = 0.80 from Table 1 to the
Wang [69] data for 750µg IV and SC doses in log and linear scales, respectively.
Figure 6(a-b) gives linear and log scale plots of the simulations of (68),(69)
with the Nelim = 0.80 parameter set from Table 1 for an IV administration
from Krzyzanski [30]. In this case no fitting was performed; the Krzyzanski
[30] protocol is simulated using parameters obtained from fitting to the Wang
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Name Value 1 Value 2 Value 3 Value 4 Value 5 Units
Nelim 0.097478 0.6 0.71678 0.8 0.87358 −
kren 1.3142 0.45064 0.2456 0.16139 0.094597 days−1
k12 2.3004 2.2519 2.1342 2.2423 2.878 days−1
k21 407.1641 198.2403 168.2588 184.8658 259.8087 days−1
kint 394.5111 459.2721 275.2744 462.4209 632.0636 days
−1
Pow 1.7355 1.4418 1.4631 1.4608 1.4815 −
Ntot 3.9496 4.1767 4.1457 4.2009 3.606 109 cells/kg
Do = 750µg, Vd = 2178.0 mL
F 0.99752 0.75 0.75 0.75 0.98271 −
ka 3.8154 5.2142 5.0574 5.143 4.1931 days−1
Err 0.16352 0.15716 0.17901 0.18543 0.21130 −
Do = 300µg, Vd = 4754.7 mL
F 1 0.63361 0.62299 0.64466 0.71424 −
ka 6.3783 8.0804 8.0628 8.0236 7.4367 days−1
Do = 375µg, Vd = 2322.9 mL
F 0.89831 0.4801 0.48549 0.49964 0.57618 −
ka 4.18161 6.7326 6.6324 6.6133 6.1259 days−1
Table 1: Pharmacokinetic parameter estimates from the simplified G-CSF
model (68),(69) for different homeostasis elimination fractions of Nelim. Err is
defined by (71) for the 750µg dose. As described in the text, dose-dependent
drug parameters were only recalculated for the lower doses.
data, and a good fit to the data is still obtained. Figure 6(c) shows another
simulation for a slightly larger SC dose, with the same G-CSF parameters
(only the the dose-dependent drug parameters ka and F were fit, as already
noted), and we again obtain good agreement with the data.
Figure 6(d) validates the use of the Ntot simplification used for (68),(69)
by comparing Ntot to NR(t)+N(t) from the solution of the full model (1)-(17)
and to N∗R+N
∗. This demonstrates how Ntot effectively averages NR(t)+N(t)
over most of the simulation.
We characterize the parameter sets found for the simplified G-CSF model
(68),(69) by the fraction Nelim of the G-CSF that is cleared by binding and
internalisation at homeostasis. For 0 6 Nelim < 1/2 the elimination is renal
dominated at homeostasis, while for 1/2 < Nelim 6 1 the pharmacokinetics are
internalisation dominant. As already mentioned in Section 3.2, from a clinical
standpoint, it is believed that Nelim > 1/2, while a number of previously
published models including [11,30,69] have Nelim close to zero.
When we included Nelim as a parameter to be fit the results were very
sensitive to the seed values used to start the optimisation and had a ten-
dency to produce parameter sets with very low or very high Nelim (see the
Nelim = 0.097 and Nelim = 0.87358 parameter sets in Table 1), but we also
found a good fit with Nelim = 0.71678 and were able to find good fits for any
fixed value of Nelim, as seen in Figure 5 (see Table 1 for parameter sets with
Nelim = 0.6 and 0.8). Our results seem to indicate that there is at least a
one parameter family of plausible parameter sets with each set characterised
by the value of Nelim. This arises because we are fitting the simplified model
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Fig. 5: G-CSF PK parameter fitting results of (68),(69) with parameter val-
ues taken from Table 1 with Nelim = 0.80. In both panels, a 750 µg dose is
administered following the protocol described in Wang [69]. Blue lines with
data: digitised data median values, red solid lines: model solution with esti-
mated parameters, black dashed lines: maximum and minimum values of the
digitised data.
(68),(69) without any data for the bound G-CSF concentrations. If the model
(68),(69) were linear then parameter identifiability theory would require data
from both components of the solution in order to identify unique parameters
in the model. Even though (68),(69) is nonlinear, the lack of any bound G-CSF
data allows us to fit the unbound G-CSF concentrations with different param-
eter sets, which will result in different solutions for the unmeasured bound
G-CSF concentrations. In Section 4.4 we will see that different G-CSF kinetic
parameter sets will result in similar G-CSF responses, but markedly different
neutrophil dynamics. The small differences in the reported errors Err in Ta-
ble 1 are not sufficient alone to make a definitive judgement of which is the
optimal parameter set. In the following sections we will study the response of
the full system (1)-(17) not just to exogenous G-CSF but also chemotherapeu-
tic treatment (both alone and with prophylactic exogenous G-CSF) which will
lead us to conclude that the PK parameters from Table 1 with Nelim = 0.80
produce the best model responses to a variety of scenarios.
As seen in Table 1, the estimates obtained for Ntot are significantly larger
than [N∗R +N
∗]. However as Figure 6(d) shows for a 750µg dose administered
by a 25 minute IV infusion, Ntot is an approximate average for [NR(t) +N(t)]
over the initial part of the simulation. This, along with the similarity between
the results given by (4)-(5) and the full model (as illustrated in Figure 2)
gives us confidence not only in the simplified model (68)-(69) for estimating
the G-CSF kinetic parameters, but also provides additional confirmation that
the marrow reservoir neutrophils NR(t) must be included along with the total
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Fig. 6: G-CSF pharmacokinetic parameter fitting results of (68),(69) with
parameter values taken from Table 1 with Nelim = 0.80 compared for different
administration types, doses, and datasets. a) & b) A simulation of (68),(69) is
compared to data from [30] in linear and log scales. c) A simulation compared
to data from [69]. d) Neutrophil concentrations (blue line) of the full neutrophil
model (1)-(17) compared to the value of Ntot and N
∗
R + N
∗. For a to c: blue
line with data: digitised data median values, red solid line: model solution
from estimated parameters, black dashed lines–digitised data maximum and
minimum values.
blood neutrophil pool N(t) in the full kinetic G-CSF model (4)-(5) in order
to reproduce the observed physiological response.
4.3 Parameter estimates from G-CSF knockout
Several murine studies [6,34] have looked at the effects of G-CSF knockout
by producing mice lacking G-CSF receptors and measuring the differences in
circulating neutrophil counts compared to wild type mice. The conclusion of
these studies is that even in the case of complete incapacity of the neutrophils
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to bind with G-CSF, neutrophil counts were still between 20 and 30% of normal
levels. This is consistent with G-CSF not being the sole cytokine to regulate
neutrophil production. Consequently we will ensure that our model produces
reduced but non-zero circulating neutrophil concentrations in the complete
absence of G-CSF, and so in this section we consider the behaviour of the
equations defining neutrophil production when G1 ≡ G2 ≡ 0. In that case
the four G-CSF dependent functions take values κ(0) = κmin, ηNP (0) = η
min
NP
,
VNM(0) ∈ (0, 1) (by (33)), and ϕNR(0) ∈ (0, ϕ∗NR) (by (31)).
We let N∗ko denote the total blood neutrophil pool under G-CSF knockout
and define the ratio
Cko = N
∗
ko/N
∗. (77)
Let θ = RPko/R
∗
P be the ratio of the rate of cells leaving proliferation in
the absence of G-CSF to the rate of cells leaving proliferation at homeostasis.
Using (47) and a similar calculation for RPko we obtain
θ =
RPko
R∗P
=
κminQ∗eτNP η
min
NP
κ∗Q∗eτNP η
∗
NP
=
κmin
κ∗
eτNP η
∗
NP
(µ−1), (78)
where we also introduce the second auxiliary parameter
µ = ηminNP /η
∗
NP 6 1, (79)
which measures the fractional reduction in the proliferation rate at knockout.
In (78) we have assumed that the number of stem cells is unchanged at knock-
out. Since the differentiation rate to neutrophils will be decreased from κ∗ to
κmin in the absence of G-CSF, the number of stem cells will actually increase,
but using (44) and (6) this increase can be calculated and is found to be less
than 1% for our model parameters.
For given values of θ, µ and eτNP η
∗
NP we will use (78) to determine the
ratio κmin/κ∗. Since κmin 6 κ∗ (see (32)), (78) implies that θ 6 eτNP η
∗
NP
(µ−1).
Rearranging this gives a lower bound for µ, from which obtain the constraint
µ ∈
(
1 +
ln(θ)
τNP η
∗
NP
, 1
)
. (80)
Here µ = 1 corresponds to a constant proliferation rate independent of G-CSF,
with the reduced production of neutrophils at knockout caused by a reduc-
tion of the differentiation rate κ. If µ is equal to its lower bound then κ is
constant independent of G-CSF concentration, and the reduced production of
neutrophils is caused by the reduced effective proliferation rate ηNP . For inter-
mediate values of µ, both κmin and ηminNP are reduced from their homeostasis
values, and µ acts as a tuning parameter to weight the relative contribu-
tion of each mechanism with κmin/κ∗ a monotonically decreasing function of
µ = ηminNP /η
∗
NP
.
A value for θ can be computed by studying the dynamics in the absence of
G-CSF after the proliferation stage. Letting N∗ko and N
∗
Rko denote the number
of neutrophils at knockout in the total blood pool and in the marrow reservoir
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respectively, the rate that cells enter and leave circulation should be equal
implying that γNN
∗
ko = ϕNR(0)N
∗
Rko, or
N∗Rko =
1
ϕNR(0)
γNN
∗
ko. (81)
The rate RMko that mature neutrophils are created at knockout is then equal
to the rate that neutrophils enter and leave the marrow reservoir, and hence
RMko = (ϕNR(0) + γNR)N
∗
Rko = γNN
∗
ko
(
1 +
γNR
ϕNR(0)
)
. (82)
During G-CSF knockout, the maturation time is given by aNM /VNM(0), during
which cells die at a constant rate γNM (which is not affected by G-CSF). Hence
the rate RPko that cells exit proliferation in the absence of G-CSF is related
to RMko by
RPkoe
−γNM
aNM
VNM
(0) = RMko.
Thus,
RPko = e
γNM
aNM
VNM
(0)RMko = γNN
∗
ko
(
1 +
γNR
ϕNR(0)
)
e
γNM
aNM
VNM
(0) . (83)
A similar calculation yields R∗P , the rate that cells leave proliferation at home-
ostasis (with G-CSF), as
R∗P = γNN
∗
(
1 +
γNR
ϕ∗NR
)
eγNM aNM . (84)
Then
θ =
RPko
R∗P
= Cko
ϕNR(0) + γNR
ϕ∗NR + γNR
exp
[
aNMγNM
( 1
VNM(0)
− 1
)]
, (85)
where Cko is defined by (77).
4.4 Estimating the Pharmacodynamic Parameters
We still require estimates for six parameters, µ, bNP , Vmax, bV , bG and ϕ
max
NR
in the functions defining the pharmacodynamic effects of G-CSF on the neu-
trophil production and mobilisation.
We digitised data from Wang [69] for average circulating neutrophil concen-
trations for three days following a 375µg and a 750µg 25-minute IV infusion.
The data also contained circulating G-CSF concentrations, but we did not
use the G-CSF concentrations for fitting. As in Section 4.2, instead of fitting
directly to the data points we used it to to define two continuous functions
N375dat (t) and N
750
dat (t), one for each dose, and fit the response of the full model
(1)-(17) to these functions.
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The fitting is difficult because no data is available for reservoir or stem cell
concentrations, and the circulating neutrophil concentrations are only mea-
sured for three days after the infusion. Since the proliferation time for neu-
trophil precursors is about a week, this data cannot be used to fit any stem
cell parameters, as no cells that commit to differentiate to the neutrophil line
after the infusion will reach circulation during this time (which is why we do
not re-estimate any stem cell parameters in the current work). Although at
homeostasis it also takes about a week for cells to traverse maturation and the
marrow reservoir, these processes are greatly sped up after G-CSF adminis-
tration, and cells that are in proliferation at the time of the infusion can reach
circulation within a day, enabling us to estimate relevant parameters.
After three days the neutrophil concentrations have not returned to their
homeostatic values. If parameters are fit just using this short interval of data,
we found parameters which gave good fits to the circulating neutrophil concen-
trations over the first three days, but for which the neutrophil concentrations
then under went very large deviations from homeostasis values lasting months
or more. There is no evidence of a single G-CSF administration destabilis-
ing granulopoiesis [39]. Accordingly, we will require that the fit parameters
result in stable dynamics. We do this by adding artificial data points for
7 6 t 6 21 days. Accordingly we construct N375dat (t) and N750dat (t) over two
disjoint time intervals as splines through the data points for t ∈ [0, 3] and as
constant functions Ndosedat (t) = N
∗ for t ∈ [7, 21]. Since we have no data for t
between 3 and 7 days describing how the neutrophils return to homeostasis,
we do not define values for Ndosedat (t) for this time interval.
For candidate parameter values, we then used Matlab’s [38] delay differ-
ential equation solver ddesd to simulate (1)-(17) over the full 21-day time
interval. This defined the functions N375(t) and N750(t), from which we were
able to measure the error between the data and the simulated solutions using
an L2 function norm similar to the one defined in (70). For the disjoint time
intervals, we have two integrals to perform, and rescale them to carry equal
weight and hence define
‖N‖22 =
1
3
∫ 3
0
N(t)2dt+
1
14
∫ 21
7
N(t)2dt, (86)
with corresponding fitting error
Err = ‖N375dat (t)−N375(t)‖22 + ‖N750dat (t)−N750(t)‖22. (87)
Parameter estimation was performed using the fmincon function in Matlab
[38]. As in the G-CSF fitting described in Section 4.2, the error was evaluated
by sampling the functions at one thousand points (with 500 in each time
interval because of the scaling in (86)).
Instead of directly fitting the six parameters specified at the start of this
section, we let b˜V = bV /Vmax and fit to the six parameters µ, bNP , Vmax,
b˜V , ϕNR(0) and ϕ
ratio
NR
. This set of parameters is easier to fit to because the
constraints (31) and (33) then become simply ϕNR(0) > 0 and b˜V > G
∗
1, while
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the original constraints both involve more than one of the unkown parame-
ters. From (17),(30) and (78), at each step of the optimisation the six fitting
parameters define the remaining parameters via
ηminNP = µ η
∗
NP , ϕ
max
NR = ϕ
ratio
NR ϕ
∗
NR , bV = b˜V Vmax,
κmin = θκ∗e(τNP η
∗
NP
(1−µ)), bG = G∗BF
ϕmaxNR − ϕNR(0)
ϕ∗NR − ϕNR(0)
.
(88)
where θ itself is calculated from (85). The Hill coefficient of (8) was set to be
s1 = 1.5, midway within its plausible range of values, as explained in Section 5.
The estimation of µ requires some caution as its lower bound in (80)
changes at each iteration of the optimisation as θ varies, and we see from
(85) that θ itself depends on three of the parameters to which we are fit-
ting. Nonsensical results are obtained if the model is simulated with µ outside
its bounds. Since the constraint is difficult to apply, to ensure that (80) is
respected we use a penalty method. Consequently, (80) is checked at each it-
eration of the optimisation and if µ is outside of its bounds µ is reset to the
bound and after the simulation is computed Err is multiplied by the penalty
factor e|µ−µbound|
1/2
which is larger than 1 when µ 6= µbound. The error func-
tion thus penalised cannot have a minimum with µ outside of its bounds, and
so the optimisation routine is forced to find values for µ within the permissible
range.
A family of G-CSF kinetic parameter sets was reported in Table 1 in Sec-
tion 4.2. Estimates for the pharmacodynamic parameters were performed for
every parameter set in Table 1. The resulting pharmacodynamic parameters
are reported in Table 2.
Since G∗2 in the full model (1)-(17) is given by (66) which differs from the
value given by (74) for the simplified model (68),(69), the values of Gprod and
Nelim derived for the two models will also be different. In Table 2 the values
from Section 4.2 for the simplified model are referred to as Nsimpelim , and we also
state the corresponding value of Nelim for the full model from (73) using (67).
It is important to note that if µ were close to 1 and far from its lower bound,
then κmin/κ∗  1, and the wide variation in possible differentiation rates could
have potentially destabilising effects on the stem cells. However, for most of
the investigated parameter sets (except for Nsimpelim = 0.097478) with the added
‘stabilising’ data, µ was found to be essentially equal to its lower bound. In
this case κmin is almost equal to κ∗, and the rate of differentiation out of the
stem cell compartment is essentially constant and (8) is virtually independent
of the influence of G-CSF. For the current model with the imposed stabilising
data, this implies that any change in production is produced by variations in
the effective proliferation rate of (9). Without the additional data points, we
found parameter estimates where µ was far from its lower bound and κmin
was similarly lower than κ∗ but these led to unstable dynamics. As seen in
Sections 4.5 and 6, the parameter estimates obtained are shown to successfully
reproduce protocols for chemotherapy-alone and chemotherapy with adjuvant
G-CSF. Accordingly, differentiation from the hematopoietic stem cells is likely
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Name Value 1 Value 2 Value 3 Value 4 Value 5 Units
Nsimpelim 0.097478 0.6 0.71678 0.8 0.87358 −
Nelim 0.3631 0.4508 0.6204 0.7033 0.8153 −
µ 0.96381 0.86303 0.85482 0.84458 0.90768 −
bNP 0.125 0.026182 0.025994 0.022868 0.024908 ng/mL
Vmax 7.9932 7.9881 7.9697 7.867 7.994 −
b˜V 0.031250 0.031251 0.031255 0.031283 0.031261 ng/mL
ϕNR (0) 0.072801 0.026753 0.023154 0.020056 0.049852 days
−1
ϕratioNR
10.9606 11.7257 11.9442 11.3556 11.9706 −
ηminNP
1.6045 1.4367 1.4231 1.406 1.5111 days−1
ϕmaxNR
3.9897 4.2682 4.3478 4.1335 4.3574 days−1
bV 0.24979 0.24964 0.24909 0.24611 0.2499 ng/mL
bG 6.3999×10−5 0.0002107 0.00019058 0.00018924 0.00018725 −
θ 0.45978 0.18895 0.17099 0.15096 0.32529 −
κmin 0.0052359 0.0073325 0.0073325 0.0073325 0.0073325 days−1
Err 0.3482 0.3153 0.2928 0.2843 0.3762 −
Table 2: Parameter estimation results for the pharmacodynamic parameters.
Nsimpelim refers to Nelim value of the corresponding kinetic parameters for the
simplified G-CSF model given in Table 1. Nelim is the corresponding value for
the full model, then stated are the six fit parameters, followed by the dependent
parameters. The approximation error to the data is found by integrating (3)
as in (87) and comparing to Wang’s data [69] for a 375 µg and 750 µg IV
infusion of 25 minutes.
close to constant in reality but from our results, we cannot conclude that
differentiation is independent of G-CSF.
Figure 7, compares the resulting model solutions for three different values
of Nelim, two of which are shown to be less optimal. Also included are the
corresponding G-CSF predictions without any re-estimation from the values
obtained in Section 4.2. For Nelim = 0.097478, the G-CSF response is well
predicted as seen in Figure 7b but because of the renal domination of these
parameters, the cytokine paradigm fails in the endogenous-only case. More-
over, repeated administrations of exogenous G-CSF will not accumulate per
clinical observations. The G-CSF response seems to be well characterised by
the Nsimpelim = 0.87358 parameters in Figure 7f however the dynamics of the
neutrophil response in Figure 7e do not stay within the data bounds, and
so are not a good fit. Using Nsimpelim = 0.80, both the neutrophil and G-CSF
responses are successfully predicted in Figures 7c and 7d. The two sets with
the lowest errors (Nsimpelim = 0.71678 and N
simp
elim = 0.8) were used to determine
parameters relating to the pharmacodynamic effects of chemotherapy, which
is discussed in Section 4.5.
4.5 Estimation of Chemotherapy Related Parameters
To estimate parameters in (38) and (40), data from the results of the Phase I
clinical trial of Zalypsis R© were digitised from Gonza´lez-Sales [22]. Unlike the
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Fig. 7: Simulations of the full model (1)-(17) for various parameter sets
with different Nelim values. Left: Circulating neutrophil concentrations in
109cells/kg over 21 days, with the first three days shown as an inset. Right:
The corresponding circulating G-CSF concentrations. Blue lines with data:
digitised data from Figure 7 (neutrophil concentrations) and Figure 6 (G-CSF
concentrations) of Wang [69], red solid lines: model solution, black dashed lines:
maximum and minimum digitised data values from Figure 7 and Figure 6 of
[69], yellow dashed lines: respective homeostatic values.
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data used for fitting in Sections 4.2 and 4.4, here the protocols differ from
one subject to the next and are reported per patient. All dosing regimens
were as stated [22] with doses scaled by body surface area (BSA). Since the
subjects were patients undergoing anti-cancer treatments, deviations from the
prescribed protocols were frequent. Thus only subjects in the top row (A, B)
and bottom row (D, E) of Figure 3 in [22] were retained for our analyses.
As with the parameter estimation of the two previous sections, we de-
fine the function N
chj
dat (t) from a spline fit to the data, where j = A,B,D,E
corresponds to each of the retained subjects. Likewise, the function N chj (t)
was defined from the solution from the DDE solver ddesd in Matlab [38]
for each patient. When the subject was administered two or more cycles of
chemotherapy, we took time intervals corresponding to the first two cycles.
Thus, the time spans differed for each subject-specific fitting procedure and
were: tspanA = [0, 43], tspanB = [0, 41], tspanC = [0, 47], and tspanD = [0, 61]. As
explained in Section 5, to account for each subject’s baseline ANC, we adjust
a scaling factor so our homeostasis N∗ value matches each individual’s. We
have previously shown the robustness of a similar model to pharmacokinetic
interindividual and interoccasion variability which substantiates this adjust-
ment and the use of average values in physiological models [10]. For each of
the four patients, we define the integrals
1
|tspanj |
∫ max(tspanj )
min(tspanj )
N(t)2dt, (89)
where j = A,B,D,E. To find average parameter values which fit to all four
patients together, we further defined the average error in the L2 function norm
of (70) between the simulated solutions and the data by
Err =
1
4
∑
j
‖N chj (t)−N chj(t)dat ‖22. (90)
Name Value 1 Value 2 Units
Nsimpelim 0.71678 0.8 −
Nelim 0.6204 0.7033 −
hQ 0.0071122 0.0079657 −
EC50 0.78235 0.72545 ng/mL
sc 0.90568 0.89816 −
ηinfNP
0 0 days−1
Err 0.17068 0.16965 −
Table 3: Results of the parameter estimation of chemotherapy effects values.
Parameters hQ, η
inf
NP
, sc, and EC50 were then estimated using the lsqcurve-
fit optimisation routine in Matlab [38] and similarly averaged. These values
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Fig. 8: Results from the chemotherapy parameter fitting for Nsimpelim = 0.80
parameters over two chemotherapy cycles. Model solutions were obtained us-
ing the parameters given in Table 2 and by simulating the full model (1)-
(17). Chemotherapeutic concentrations are obtained via (37) and (40). Equa-
tion (18) is replaced by (38) and solved by using (39) Data and experimental
protocols from Figure 3 of Gonza`lez-Sales [22]. Blue lines with data: digitised
data, red solid lines: model solution.
are reported in Table 3 and the results of Figure 8 were obtained from sim-
ulations using these parameters. For each of hQ, EC50, sc, and η
inf
NP
, similar
estimates were obtained for Nsimpelim = 0.71578 and N
simp
elim = 0.8, although the
average error of Nsimpelim = 0.8 is slightly smaller and was accordingly retained
as optimal.
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5 Parameter Values
Here we summarise the parameter values we use in the full model taken from
experimental results and the fitting procedures described in Section 4. For the
model to be self-consistent these parameters must be positive and satisfy the
parameter constraints that we derived above, namely: (30), (31), (33), (59),
(60) and (80).
The main model parameters are stated in Table 4. For the stem cells we
reuse parameter values for Q∗, γQ, τQ, fQ, s2 and β(Q∗) from previous mod-
elling (sometimes rounding them to fewer significant figures). The value of θ2
is obtained by evaluating (6) at homeostasis and rearranging to obtain
θ2 =
[
(Q∗)s2β(Q∗)
fQ − β(Q∗)
] 1
s2
. (91)
In Table 4 we quote a value of θ2 to five significant figures, but in our com-
putations all parameters defined by formulae are evaluated to full machine
precision. This ensures that our differential equation model has a steady state
exactly at the stated homeostasis values.
For the neutrophil parameters we mainly take experimental values from
the work of Dancey [14] and use the formulae of Section 4.1 to determine the
related model parameter values. However, some choices and adjustments need
to be made to ensure that the values are consistent with the model. Dancey [14]
measured the circulating neutrophil pool to be 0.22 × 109cells/kg and the
recovery rate to be 0.585 from which we obtain the total blood neutrophil
pool N∗ (including the marginated pool) to be
N∗ =
0.22
0.585
≈ 0.3761× 109cells/kg. (92)
Since N(t) measures the total blood neutrophil pool in units of 109cells/kg
some care needs to be taken when comparing to data, where absolute neu-
trophil counts (ANC) measure the circulating neutrophil pool in units of
cell/µL. Based on 70 kg of body mass and 5 litres of blood we have the default
conversion factor for healthy subjects of
ANC = 0.585× 70
5
× 1000×N(t) = 8190N(t) cell/µL. (93)
This gives a baseline homeostasis ANC of 8190N∗ = 3080 cell/µL, well within
the accepted normal range of 1800− 7000 cells/µL [50]. When comparing our
model to data for individuals with different baseline ANCs (as in Section 4.5)
we adjust the conversion factor (93), but not the parameter values in our
model, so that N∗ gives the homeostasis ANC of the data.
Dancey [14] measures the proliferation and maturation phases at home-
ostasis to be N∗P = 2.11×109cells/kg (mainly promyelocytes and myelocytes)
and N∗M = 3.33×109cells/kg (metamyelocytes and bands). Using these num-
bers in the calculations in Section 4.1 results in a proliferation time τNP defined
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Name Interpretation Value Units Source
γQ HSC apoptosis rate 0.1 days
−1 [5,11]
τQ Time for HSC re-entry 2.8 days [35,4,33,11]
A∗Q HSC Amplification Factor 1.5116
† − Eq. (7)
fQ Maximal HSC re-entry rate 8 days
−1 [4,5,11]
s2 HSC re-entry Hill coefficient 2 − [4,5,11]
θ2 Half-effect HSC concentration 0.080863† 106cells/kg Eq. (91)
κδ HSC differentiation rate to other lines 0.014665
† days−1 Eq. (45)
κmin HSC-neutrophil minimal differentiation rate 0.0073325† days−1 Eq. (88)
κ∗ HSC-neutrophil homeo differentiation rate 0.0073325† days−1 Eq. (45)
s1 HSC-neutrophil differentiation Hill coefficient 1.5 − Eq. (96)
η∗NP Neutrophil homeostasis effective proliferation rate 1.6647
† days−1 Eq. (63)
bNP Neutrophil proliferation M-M constant 0.022868 ng/mL Fit Table 2
ηminNP
Neutrophil minimal proliferation rate 1.4060 days−1 Eq. (88)
τNP Neutrophil proliferation time 7.3074
† days Eq. (64)
Vmax Maximal neutrophil maturation velocity 7.8670 − Fit Table 2
bV maturation velocity half-effect concentration 0.24611 ng/mL Eq. (88)
aNM Homeostasis neutrophil maturation time 3.9 days [14,25] & (95)
γNM Neutrophil death rate in maturation 0.15769
† days−1 Eq. (57)
ϕ∗NR Homeostasis Reservoir Release rate 0.36400
† days−1 Eq. (52)
ϕmaxNR
Maximal Reservoir Release rate 4.1335† days−1 Eq. (88)
bG Reservoir Release half-effect concentration 1.8924× 10−4 − Eq. (88)
γNR Neutrophil death rate in reservoir 0.0063661
† days−1 Eq. (54)
γN Neutrophil Removal Rate from Circulation 35/16 days
−1 Eq. (51)
G∗1 Homeostasis Free G-CSF Concentration 0.025 ng/mL [71,26,2,30]
G∗BF Homeostasis neutrophil receptor bound fraction 1.5823× 10−5 − Eq. (16)
Gprod Endogenous G-CSF production rate 0.014161
† ng/mL/day Eq. (67)
V Bound G-CSF conversion factor 0.525
ng/mL
109cells/kg
Eq. (65)
kren G-CSF renal elimination rate 0.16139 days−1 Fit Table 1
kint G-CSF effective internalisation rate 462.42 days
−1 Fit Table 1
k12 G-CSF Receptor binding coefficient 2.2423 (ng/mL)−Powdays−1 Fit Table 1
k21 G-CSF Receptor unbinding rate 184.87 days−1 Fit Table 1
Pow Effective G-CSF binding coefficient 1.4608 − Fit Table 1
Table 4: Model Parameters. † – these parameters are displayed to 5 significant
figures here, but the value is actually defined by the stated equation, and in
simulations/computations we use the stated formula to define the value to
machine precision.
by (64) of about 26 days. In our model τNP is the time from when the HSC
first commits to differentiate to the neutrophil line to the end of proliferation
of the neutrophil precursors. Although this time has never been definitively
measured, 26 days seems to be too long. This is confirmed by the time to neu-
trophil replenishment in the blood after both allogenic and autologous stem
cell transplantation [1,7], where circulating neutrophils are seen two weeks af-
ter the transplant. We suspect that this overly long proliferation time results
from the simplification in our model of considering proliferation as a single
homogenous process as detailed in Section 3.3.
To obtain a more realistic proliferation time of around a week, close
to the 6.3 days that Smith [62] states, we keep the total of N∗P + N
∗
M =
5.44×109cells/kg as found by Dancey [14], but redistribute cells between pro-
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Name Interpretation Value Units Source
Q∗ HSC homeostasis concentration 1.1 106cells/kg [4,33,11]
β(Q∗) HSC re-entry rate 0.043 days−1 [35,11]
N∗ Homeostasis Total Blood Neutrophil Pool 0.22/0.585 109cells/kg Eq. (92)
N∗R Homeostasis Neutrophil Reservoir Concentration 2.26 10
9cells/kg [14]
N∗P Homeostasis Neutrophil Proliferation Concentration 0.93 10
9cells/kg Eq. (94)
N∗M Homeostasis Neutrophil Maturation Concentration 4.51 10
9cells/kg Eq. (94)
G∗2 Homeostasis bound G-CSF concentration 2.1899× 10−5 ng/mL Eq. (66)
τ∗NR Homoeostasis Neutrophil mean time in reservoir 2.7 days [14,25] & (95)
τ∗NC Homoeostasis Neutrophil mean time in circulation 16/35 days [14]
τ1/2 Circulating Neutrophil half-removal time 7.6 hours [14]
A∗N Homeostasis neutrophil proliferation+maturation amplification 1.0378× 105† − Eq. (61)
b˜V scaled maturation half-effect concentration 0.031283 ng/mL Fit Table 2
ϕratioNR
Ratio of maximal and homeostasis reservoir release rates 11.356 − Fit Table 2
ϕNR (0) Minimal reservoir release rate 0.020056 days
−1 Fit Table 2
θ Ratio of rate cells leave proliferation at knockout to homeostasis 0.15096 − Eq. (85)
Cko Knockout total blood neutrophil pool fraction 0.25 − [6,34]
µ Ratio of minimal and homeostasis proliferation rates 0.84458 − Fit Table 2
Table 5: Auxiliary Parameters which are not in the model in Section 2, but
whose values are used to define other parameters. † – these parameters are
displayed to 5 significant figures here, but the value is actually defined by the
stated equation, and in simulations/computations we use the stated formula
to define the value to machine precision.
liferation and maturation and set
N∗P = 0.93×109cells/kg, N∗M = 4.51×109cells/kg. (94)
Dancey [14] measured the half removal time of neutrophils from circu-
lation to be t1/2 = 7.6 hrs. Accordingly, using (51) and rounding, we set
γN = 35/16 = 2.1875 days
−1 and obtain τ∗NC as the reciprocal of this.
Then equation (58) imposes the constraint that aNM < 5.4823 days. If we
set aNM = 3.9 days close to the value of 3.8 days found by Hearn [25], then
(60) imposes the constraint that τ∗NR ∈ (1.9543, 2.7472). Hence we take
aNM = 3.9 days, τ
∗
NR = 2.7 days, (95)
so that both constraints are satisfied, and aNM + τ
∗
NR
= 6.6 days, the value
given in [14]. The rest of the neutrophil homeostasis parameters are calculated
using the formulae of Section 4.1, paying attention in (61) to multiply Q∗ by
10−3 to convert it to the same units as N∗R.
The G-CSF pharmacokinetic parameters are fit using the simplified G-
CSF model (68),(69) as described in Section 4.2. This produces multiple, but
equally plausible, parameter sets but as described in subsequent sections not all
of these result in good fits to data when we consider the neutrophil response
of the full model (1)-(17) to administrations of G-CSF or of chemotherapy.
Consequently as stated in Section 4.5, to obtain the best responses of the
system to these scenarios we use the fourth set of pharmacokinetic parameters
from Table 1 which for the simplified G-CSF model have Nsimpelim = 0.8 to define
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kren, k12, k21, kint and Pow, as well as the exogenous G-CSF parameters Vd,
F , ka (where the last three are dose dependent). Equations (66), (67) and (73)
then define G∗2, Gprod and Nelim = 0.7033 for the full model.
At G-CSF knockout, from [6,34] we have Cko ∈ [0.2, 0.3], so it is natural
to set Cko = 0.25.
For the pharmacodynamic parameters, similar to Pow, arguments could
be made for choosing s1 = 1 or s1 = 2, but having fit Pow and finding it close
to 1.5, we will simply set
s1 = 1.5 (96)
to reduce the number of parameters that need to be fit by one. The remaining
pharmacodynamic parameters µ, bNP , Vmax, b˜V , ϕNR(0) and ϕ
ratio
NR
were then
fit as described in Section 4.4, with these parameters defining values of the
dependent parameters ηminNP , ϕ
max
NR
, bV and bG via (88). From Section 4.3 we
also obtain values for θ from (85) and κmin from (88). Each set of kinetic pa-
rameters from Table 1 defines a different set of pharmacodynamic parameters
as reported in Table 2, but as noted already we prefer the parameter set for
Nsimpelim = 0.80 which corresponds to Nelim = 0.7033.
The full set of parameter values for our combined neutrophil and G-CSF
model (1)-(17) are given in Table 4, along with their units, interpretation and
source. Since some of these parameters are defined by equations involving aux-
iliary parameters that do not explicitly appear in the full model we state these
parameters and their source in Table 5. Parameters related to the pharma-
cokinetics and pharmacodynamics of both of the exogenous drugs which have
not previously been stated are given in Table 6.
6 Model evaluation and functional responses
Having estimated the G-CSF pharmacokinetic, homeostasis related, and
chemotherapy pharmacodynamic parameters individually as described in Sec-
tions 4.2, 4.4, and 4.5, a convincing evaluation of the ability of the model is
to successfully predict data obtained during the concurrent administration of
both exogenous drugs. For this, as in [11], we simulated the CHOP14 protocol
described in [43] and [42] which includes the administration of both chemother-
apy and exogenous G-CSF. Although the chemotherapeutic drug modelled in
Section 3.5 is not part of the combination therapy of the CHOP14 regimen,
the cytotoxic effects of the anticancer drugs are presumed to be similar. To
compare to the CHOP14 data published in [29], we simulated a regimen of six
cycles of 14-day periodic chemotherapeutic treatment with rhG-CSF treatment
beginning four days after the administration of chemotherapy and continuing
for ten administrations per cycle. As in [11], the simulated dose of 4 µg of
Zalypsis R© was selected from the optimal regimens identified in [22] and per
the CHOP14 protocol outlined in [43,42], ten 300 µg doses of subcutaneous
G-CSF were simulated per cycle. The lower dose of 300 µg was selected since
we assumed an average weight of 70kg per patient throughout.
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Name Interpretation Value Units Source
Filgrastim
300 mcg dose
Vd Volume of distribution 4754.7 mL Fit Table 1
F Bioavailable fraction 0.64466 − Fit Table 1
ka Subcutaneous rate of absorption 8.0236 days−1 Fit Table 1
375 mcg dose
Vd Volume of distribution 2322.9 mL Fit Table 1
F Bioavailable fraction 0.49964 − Fit Table 1
ka Subcutaneous rate of absorption 6.6133 days−1 Fit Table 1
750 mcg dose
Vd Volume of distribution 2178.0 mL Fit Table 1
F Bioavailable fraction 0.75 − Fit Table 1
ka Subcutaneous rate of absorption 5.143 days−1 Fit Table 1
ZalypsisR©
kfp Rate of exchange from compartment f to p 18.222 days
−1 [41]
ksl1p Rate of exchange from compartment sl1 to p 0.6990 days
−1 [41]
kpf Rate of exchange from compartment p to f 90.2752 days
−1 [41]
kpsl1 Rate of exchange from compartment p to sl1 8.2936 days
−1 [41]
kelC Rate of elimination 132.0734 days
−1 [41]
ksl2f Rate of exchange from compartment sl2 to f 62.5607 days
−1 [41]
kfsl2 Rate of exchange from compartment f to sl2 9.2296 days
−1 [41]
BSA Body surface area 1.723 m2 [41]
hQ Effect of chemotherapy on Q(t) 0.0079657 − Fit Table 3
EC50 Half-maximal effect of chemotherapy on ηNP 0.75390 − Fit Table 3
sc Chemotherapy effect Hill coefficient 0.89816 − Fit Table 3
ηinfNP
Proliferation rate with infinite chemotherapy dose 0 days−1 Fit Table 3
Table 6: Exogenous drug administration parameters determined by parameter
fitting as explained in Sections 4.2 and 4.5. For Zalpysis R©, p: plasma/central
compartment, f : fast-exchange tissues, sl1: first slow-exchange tissues, sl2:
second slow-exchange tissues.
Figure 9 shows the result of the neutrophil response comparison of the
model’s prediction to the clinical data. Unlike experimental settings where
information on the HSCs, the marrow neutrophils, and the bound G-CSF con-
centrations are unavailable, the model’s solutions for Q(t), NR(t), and G2(t)
are easily obtainable and provide insight into not only the mechanisms re-
sponsible for myelosuppresion during chemotherapy, but also ways in which
this toxicity might be avoided. In Figure 10, the HSCs, neutrophils in the
marrow reservoir, and bound and unbound G-CSF are all seen to converge
to periodic responses. However, while the reduction in HSC concentrations is
minimal (Figure 10a) the neutrophil marrow reservoir is seen in Figure 10b to
become severely depleted. This depletion is caused by the delayed effects of
the administration of chemotherapy but also the rapid transit of cells from the
reservoir into the blood caused by the introduction of exogenous G-CSF four
days post-chemotherapy (see Figure 11e below). This in turn prevents ANC
recoveries from depressed values, despite the administration of G-CSF. As in
[66] and [11], it is likely that delaying the beginning of prophylactic G-CSF
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Fig. 9: Comparison of the predicted neutrophil response to the CHOP14 pro-
tocol [43,42] for Nsimpelim = 0.80. In this regimen, 4 µg of Zalypsis
R© given by a 1
hour IV infusion is administered 14 days apart, beginning on day 0, for 6 cycles
(84 days total). Per cycle, ten administrations of 300 µg subcutaneous doses
of filgrastim are given beginning four days after the start of the chemothera-
peutic cycle and continuing to day 13 post-chemotherapy. The simulation is
compared to data from [29], presented in quartiles. In pale green: the first
quartile, in pale pink: median range, in pale blue: third quartile. Black line
with sampling points: model prediction sampled every day at clinical sampling
points, solid purple line: full model prediction.
support during chemotherapy would help to combat myelosuppresion, but this
will is a future avenue of investigation.
It can also be illuminating to study how each of the model’s functions corre-
spond to the estimated parameters to obtain further insight on the mechanisms
of granulopoiesis. Figure 11 shows the functions κ(G1), ηNP (G1), η
chemo
NP
(G1),
VNM(G1), and ϕNR(GBF ) and identifies their respective homeostatic levels.
We can see that ϕNR(GBF ) in Figure 11e, has a homeostasis concentration
ϕNR(G
∗
BF ) very close to ϕNR(0). This reflects the ability of the granulopoietic
system to respond rapidly in the case of emergencies [47] but also supports
the hypothesis that early prophylactic support with G-CSF during chemother-
apy may hasten the emptying of the reservoir due to the responsiveness of
ϕNR(GBF (t)) in particular.
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Fig. 10: Model responses to the CHOP14 protocol as described in Section 6. In
a) Q(t) over the six CHOP cycles detailed above, b), c), and d) NR(t), G1(t),
and G2(t) over three CHOP cycles.
7 Discussion
Clinically relevant translational models in medicine must not only accurately
depict different and independent treatment regimes [66], they must also be able
to reconstruct homeostatic and pathological cases which may be intervention
independent. The granulopoiesis model we have developed is physiologically-
relevant and, perhaps most importantly, provides insight beyond that which
is clinically measurable. The updated pharmacokinetic model of G-CSF, novel
in that it explicitly accounts for unbound and bound concentrations, correctly
accounts for G-CSF dynamics whereas previous one compartment models all
resulted in renal dominated dynamics. The new pharmacokinetic model also
further allows us to comment on the principle mechanisms driving the produc-
tion of neutrophils. Although the relatively small number of neutrophil pro-
genitors do not have a significant effect on G-CSF kinetics, our results suggest
that differentiation, proliferation and maturation speed are driven primarily
by signalling from G-CSF bound to neutrophil progenitors, and not from sig-
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Fig. 11: Visualisation of the granulopoiesis model’s mechanisms as functions
of their variables (solid blue lines) with their respective homeostatic and half-
effect values (purple triangles), when relevant. Red circles: homeostasis values.
nalling of G-CSF bound to mature neutrophils. We can further characterise the
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principle processes governing myelosuppression during the concurrent admin-
istration of chemotherapy and prophylactic G-CSF, which we have determined
lies in the simultaneous depletion of the marrow reservoir by high doses of ex-
ogenous G-CSF combined with fewer neutrophils reaching the reservoir due to
the cytotoxicity of the anti-cancer drug.
The modelling reported here combines a number of original approaches
to the conceptualisation of physiological, pharmacokinetic, and pharmacody-
namics models and to the estimation of parameters and model verification.
For example, traditional least squares estimation was redefined using functions
which ensured robustness and allowed for comparisons of predictions to data
over richly sampled intervals instead of at fewer data points. Moreover, the
model’s physiological realism served as a means of evaluating the suitability
of optimised parameter values so we were not relying solely on goodness-of-fit,
which can obfuscate the biological relevance of results [67]. The inclusion of the
detailed characterisations of physiological mechanisms in our model therefore
serves as a litmus test of suitability in addition to providing intuition about
the processes driving granulopoiesis.
The broader implications of the approaches outlined in this work extend
into various domains. The derivation of a delay differential equation model
with variable aging rate from an age-structured PDE, as described in Sec-
tion 3.3, is mathematically significant and its intricate nature has previously
led to previous modelling errors. As mentioned, the fitting procedures outlined
in Sections 4.2, 4.4, and 4.5 motivate the development of more refined least
squares methods and parameter estimation techniques. Additionally, the novel
pharmacokinetic model of G-CSF has ramifications with respect to the usual
approaches used by PK/PD modellers. The mischaracterisation of the elimina-
tion dynamics, despite the inclusion of internalisation terms, has led to models
which contradict what is known of the physiology. While they can characterise
certain clinical situations, like the single administration of exogenous G-CSF,
they fail when applied to more complex scenarios. Without accounting for
the entire process of neutrophil development or using physiological rationale
for a model’s parameters, one is unable to judge whether a model captures
the complicated dynamics of granulopoiesis. In the model we have developed,
we have ensured the accuracy of its predictions and the appropriateness of
its parameters through careful construction. In turn, this rational approach
has implications for the clinical practice where it can serve to optimise dosing
regimens in oncological settings and also serve to pinpoint the origins of dy-
namical neutrophil disorders like cyclic neutropenia, ultimately contributing
to the improvement of patient care and outcomes.
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